ARYL AND HETEROARYLCYCLOPROPYL OXIME ETHERS AND THEIR USE AS FUNGICIDES

Abstract: The present invention relates to certain aryl cyclopropyl oxime ether and oxime amide compounds, compositions containing these compounds, and methods for controlling fungi by the use of a fungitoxic amount of these compounds.

Description: ARYL and HETEROARYLCYCLOPROPYL OXIME ETHERS AND THEIR USE AS FUNGICIDES The present invention relates to certain aryl cyclopropyl oxime ether compounds, compositions containing these compounds, and methods for controlling fungi by the use of a fungitoxic amount of these compounds. Compounds having certain oxime ether structures are disclosed in U.S. Patent Nos. 5,194,662, 5,292,759, and 6,063,956. The disclosed compounds provide control of a variety of fungal organisms. We have discovered a select group of such cyclopropyl oxime ethers containing specific substituted aryl and heterocyclic moieties which possess unexpectedly superior fungicidal properties when compared with the genus of compounds disclosed in the aforementioned patents. The cyclop ropyloxime ethers of the present invention have the Formula (I) I wherein X is N or CH; Z is O, S, or NRg; A is hydrogen, halo, cyano, (C 1 -C 12 )alkyl, or (C 1 -C 12 )alkoxy; R x and R 8 are independently hydrogen or (C 1 -C 4 )alkyl; R 2 is hydrogen, (C^C^alkyl, haloCC j - C 4 )alkyl, (C 3 -C 6 )cycloalkyl, halo(C 3 - C 6 )cycloalkyl, (C 2 -C 4 )alkenyl, halo(C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, halo(C 2 -C 4 )alkynyl, or cyano; R 3 is hydrogen, (C r C 4 )alkyl, halo(C r C 4 )alkyl, (C 3 -C 6 )cycloaιkyl, halo(C 3 - C 6 )cycloalkyl. (C 2 - C 4 )alkenyl, halo(C 2 - C 4 )alkenyl, (C 2 - C 4 )alkynyl, or halo(C 2 - C 4 )alkynyl; R 4 and R 5 are independently hydrogen, (C^ C 4 )alkyl, halo(C 1 - C 4 )alkyl, (C 3 -C 6 )cycloalkyl, halo(C 3 -C 6 )cycloalkyl, (C 2 - C 4 )alkenyl, halo(C 2 - C 4 )alkenyl, (C 2 -C 4 )alkynyl, halo(C 2 - C 4 )alkynyl, halo, cyano, or (C r C )alkoxycarbonyl; and wherein A) R 7 is aryl or heterocyclic ring wherein the aryl or heterocyclic ring is substituted with from 2 to 5 substituents and wherein the positions on the aryl or heterocyclic ring adjacent to the bond to the cyclopropyl ring are both substituted and R 6 is hydrogen, (C r C )alkyl, halo(C 1 - C 4 )alkyl, (C 3 -C 6 )cycloalkyl, halo(C 3 -C 6 )cycloalkyl, (C 2 - C 4 )alkenyl, halo(C 2 - C 4 )alkenyl, (C 2 - C 4 )alkynyl, halo(C 2 - C 4 )alkynyl, halo, cyano, or (C 1 -C 4 )alkoxycarbonyl; or B) R 7 is an aryl or heterocyclic ring wherein the aryl or heterocyclic ring is unsubstituted or substituted from 1 to 4 substituents wherein at least one of the positions on the aryl or heterocyclic ring adjacent to the bond to the cyclopropyl ring is a hydrogen and R 6 is selected from the group consisting of (C r C )alkyl, halo(C r C 4 )alkyl, (C 3 -C 6 )cycloalkyl, halo(C 3 - C 6 )cycloalkyl, (C 2 - C 4 )alkenyl, halo(C 2 - C 4 )alkenyl, (C 2 - C 4 )alkynyl, halo(C 2 - C 4 )alkynyl, halo, cyano, or (C r C 4 )alkoxyearbonyl; and their salts, complexes, enantiomorphs, stereoisomers; and mixtures thereof. The biological activity of compounds of Formula I is greatly influenced by the interaction between the R6 and R7 groups, which are attached to the same carbon on the cyclopropyl ring, and, more specifically, by the number, type, and configuration of substituents on the aryl or heteroaryl R7, particularly those in the ortho position to the bond between the R7 group and the cyclopropyl ring, while taking into account whether the R6 group is a hydrogen or a different group. The aforementioned alkyl, alkenyl, alkynyl and (C 3 - C 6 )cycloalkyl groups may be optionally and independently substituted with up to three substituents selected from nitro, halomethyl, (Cι-C4)alkoxycarbonyl, and cyano. Unless otherwise specified herein, the term alkyl includes both branched and straight chain alkyl groups from 1 to 4 carbon atoms. Typical alkyl groups are methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, isobutyl, t-butyl, n- pentyl, isopentyl, n-hexyl, n-heptyl, isooctyl, nonyl, decyl, undecyl, dodecyl and the like. The term haloalkyl refers to an alkyl group substituted with from 1 to 3 halogens. Unless otherwise specified herein, the term alkenyl refers to an ethylenically unsaturated hydrocarbon group, straight or branched, having a chain length of from 2 to 4 carbon atoms and 1 ethylenic bonds. The term haloalkenyl refers to an alkenyl group substituted with from 1 to 3 halogen atoms. The term alkynyl refers to an unsaturated hydrocarbon group, straight or branched, having a chain length of from 2 to 4 carbon atoms and 1 acetylenic bonds. Unless otherwise specified herein, the term aryl includes phenyl and naphthyl which maybe substituted with up to five substituents independently selected from halogen, cyano, nitro, trihalomethyl, trihalomethoxy, phenyl, phenoxy. (C r C 4 )aikyl, (C 3 -C 6 )cycloalkyl, (C 2 -C 4 )alkenyl, (C j^ -C^alkoxy, (C r C 4 )alkylthio, (C j -C^alkylsulfoxide, halo (^-C^ alkyl, halo(C 1 -C 4 )alkoxy, halo(C 3 - C 6 )cycloalkyl, halo(C 2 -C 4 )alkenyl, or (C 1 -C 4 )alkoxycarbonyl. Typical phenyl substituents, wherein at least one of the positions on the phenyl ring adjacent to the bond to the cyclopropyl ring is substituted with hydrogen include but are not limited to 2-chloro, 3-chloro, 4-chloro, 2-fluoro, 3-fluoro, 4-fluoro, 2-bromo, 3- bromo, 4-bromo, 2-methyl, 3-methyl, 4-methyl, 2-trifluoromethyl, 3- trifluoromethyl, 4-trifluoromethyl, 2-methoxy, 3-methoxy, 4-methoxy, 2- trifluoromethoxy, 3-trifluoromethoxy, 4-trifluoromethoxy, 2-cyano, 3-cyano, 4- cyano, 2,3-dichloro, 2,3-difluoro, 2,3-dibromo, 2,3-dimethyl, 2,3-dimethoxy, 2,3- bis(trifluoromethyl), 2,3bis-(trifluoromethoxy), 2,4-difluoro, 2,4-dichloro, 2,4- dibromo, 2,4-dimethyl, 2,4-dimethoxy, 2,4-bis(trifluoromethyl), 2,4- bis(trifluoromethoxy), 2,5-difhιoro, 2,5-dichloro, 2,5-dibromo, 2,5-dimethyl, 2,5- dimethoxy, 2,5-bis(trifluoromethyl), 2,5-bis-(trifluoromethoxy), 3,4-difluoro, 3,4- dichloro, 3,4-dibromo, 3,4-dimethyl, 3, 4- dimethoxy, 3,4-bis(trifluoromethyl), 3,4- bis(trifluoromethoxy), 3,5-difluoro, 3,5-dichloro, 3,5-dibromo, 3,5-dimethyl, 3,5- bis(trifluoromethyl), 3,5-bis(trif-uoro-methoxy), 2,3,4-trifluoro, 2,3,4-trichloro, 2,3,4-tribromo, 2,3,4-trimethyl, 2,3,4-trimethoxy, 2,3,4-tris(trifluoromethyl), 2,3,4-tris(trifluoromethoxy), 2,3,5-trifluoro, 2,3,5-trichloro, 2,3,5-tribromo, 2,3,5- trimethyl, 2,3,5-tris(trifluoromethyl), 2,3,5-tris(trifluoromethoxy), 2,4,5-trifluoro, 2,4,5-trichloro, 2,4,5-tribromo, 2,4,5-trimethyl, 2,4,5-trimethoxy, 2,4,5- tris(trifluoromethyl), 2,4,5-tris(trifluoromethoxy) , 3,4,5-trifluoro, 3,4,5-trichloro, 3,4,5-tribromo, 3,4,5-trimethyl, 3,4,5-trimethoxy, 3,4,5-tris(trifluoromethyl), 3,4,5-tris(trifluoromethoxy), 2,3,4,5-tetrafluoro, 2,3,4,5-tetrachloro, 2,3,4,5- tetrabromo, 2,3,4,5-tetramethyl, 2,3,4,5-tetramethoxy, 2,3,4,5- tetra(trifluoromethyl), and 2,3,4,5-tetra(tetrafluoromethoxy. Typical phenyl substituents, where both positions on the phenyl ring adjacent to the bond to the cyclopropyl rings are substituted include but are not limited to 2,6-dichloro, 2,3,6-trichloro, 2,4,6-trichloro, 2,6-difluoro, 2,3,6-trifluoro, 2,4,6-trifluoro, 2,6-dibromo, 2,3,6-tribromo, 2,4,6-tribromo 2,3,4,6-tetrachloro, 2,3,5,6-tetrachloro, 2,3,4,5,6-pentachloro, 2,3,4,6-tetrabromo, 2,3,5,6-tetrabromo, 2,3,4,5,6-pentabromo, 2,3,4,6-tetrafluoro, 2,3,5,6-tetrafluoro, 2,3,4,5,6- pentafluoro, 2,6-dimethyl, 2,3,6-trimethyl, 2,4,6-trimethyl, 2,6-dimethoxy, 2,3,6- trimethoxy, 2,4,6-trimethoxy, 2,6-diethoxy, 2,3,6-triethoxy, 2,4,6-triethoxy, 2,3,4,6-tetramethyl, 2,3,5,6-tetramethyl, 2,3,4,5,6-pentamethyl, 2,3,4,6- tetramethoxy, 2,3,5,6-tetramethoxy, 2,3,4,5,6-pentamethoxy, 2,3,4,6- tetraethoxy, 2,3,5,6-tetraethoxy, 2,3,4,5,6-pentaethoxy, 2,6-dicyano, 2,3,6- tricyano, 2,4,6-tricyano, 2,6-dinitro, 2,6-diphenyl , 2,6-diphenoxy, 2,6-dibenzyl, 2,6-bis(trifluoromethyl), 2,3,6-tris(trifluoromethyl), 2,4,6-tris-(trifluoro-methyl), 2,3,4,6-tetra(trifluoromethyl), 2,3,5,6-tetra(trifluoromethyl), 2,3,4,5,6- penta(trifluoromethyl), 2,6-bis-(trifluoromethoxy), 2, 3,6-tris(trifluoromethoxy), 2,4,6-tris(trifluoromethoxy), 2,3,4,5-tetra(trifluoromethoxy), 2,3,4,6-tetra- (trifluoro-methoxy), 2,3,5,6-tetra(trifluoromethoxy), 2,3,4,5,6- penta(trifluoromethoxy), 2-bromo-6-chloro, 2-bromo-6-fluoro, 2-bromo-6- (trifluoromethyl), 2-bromo-6-methyl, 2-bromo-6-methoxy, 2-bromo-6- (trifluoromethoxy), 2-bromo-6-cyano, 2-chloro-6-fluoro, 2-chloro-6- (trifluoromethyl), 2-chloro-6-methyl, 2-chloro-6-methoxy, 2-chloro-6- trifluoromethoxy), 2-chloro-6-cyano, 2-fluoro-6-(trifluoromethyl), 2-fluoro-6- methyl, 2-fluoro-6-methoxy, 2-fluoro-6-(trifluoromethoxy), 6-cyano-2-fluoro, 2- methyl-6-(trifruoromethyl), 6-methoxy-2-methyl, 2-methyl-6-(trifluoromethoxy), 6-cyano-2-methyl, 3,6-dichoro-2-fluoro, 3-chloro-2,6-difluoro, 4-chloro-2,6- difluoro, 2-bromo-3,6-dichoro, 2,3-dibromo-6-chloro, 3-chloro-2,6-dibromo, 2,6- dichloro-3-fluoro, 2,3-dichloro-6-fluoro, 2-chloro-3,6-difluoro, 3-bromo-2,6- dichloro, 3-bromo-2,6-fluoro, 3-bromo-6-chloro-2-fluoiO, 2-bromo-5-chloro-6- fluoro, 2,6-dibromo-3-fluoro, 2,5-dibromo-6-fluoro, 2,4-dichloro-6-fluoro, 2,6- chloro-4-fluoro, 2,4,-dichloro-6-bromo, 2,6-dichloro-4-bromo, 2,4-difluoro-6-chloro, 2,4-difluoro-6-bromo, 2,6-difluoro-4-bromo, 2,4-dibromo-6-fluoro, 2,4-dibromo-6- chloro, 2,6-dibromo-4-chloro, 2,6-dibromo-4-fluoro, 2,4-dichloro-6-methyl, 2,6- dichloro- -methyl, 2-chloro-4,6-dimethyl, 4-chloro-2,6-dimethyl, 2,4-difluoro-6- methyl, 2,6-difluoro-4-methyl, 2-fluoro-4,6-dimethyl, 4-fluoro-2,6-dimethyl, 2,4- dibromo-6-methyl, 2,6-dibromo-4-methyl, 2-bromo-4,6-dimethyl, 4-bromo-2,6- dimethyl, 2,4-dichloro-6-methoxy, 2,6-dichloro-4-methoxy, 2-chloro-4,6- dimethoxy, 4-chloro-2,6-dimethoxy, 2,4-difluoro-6-methoxy, 2,6-difluoro-4- methoxy-, 2-fluoro-4,6-dimethoxy, 4-fluoro-2,6-dimethoxy, 2,4-dibromo-6- methoxy, 2,6-dibromo-4-methoxy, 4-bromo-2,6-dimethoxy, 4-bromo-2,6- dimethoxy, 2,4-dichloro-6-(trifluoromethyl), 2,6-dichloro-4-(trifluoromethyl), 2- chloro-4,6-bis(trifluoromethyl), 4-chloro-2,6-bis(trifluoromethyl), 2,4-diflnoro-6- (trifluoromethyl), 2,6-difluoro-4-(trifluoromethyl), 2-fluoro-4,6- bis(trifluoromethyl), 4-fluoro-2,6-bis(trifluoromethyl), 2,4-dibromo-6- (trifluoromethyl), 2 ! 6-dibromo-4-(trifluoromethyl), 2-bromo-4,6- bis(trifluoromethyl), 4-bromo-2,6-bis(trifluoromethyl), 2-chloro-4,6- bis(trifluoromethoxy), 4-chloro-2,6-bis(trifluoromethoxy), 2,4-difluoro-6- (trifluor omethoxy) , 2 , 6- difluoro - 4- (trifluoromethoxy) , 2 -fluoro- 4, 6 -bis (trifluoro - methoxy), 4-fluoro-2,6-bis(trifluoromethoxy), 2,4-dibromo-6-(trifluoromethoxy), 2,6-dibromo-4-(trifluoromethoxy), 2-bromo-4,6-bis(trifluoromethoxy), 4-bromo- 2,6-bis(trifluoromethoxy), 4,6-dichloro-2-nitro, 4,6-dibromo-2-nitro, 4,6-difluoro- 2-nitro, 2,6-dichloro-4-nitro, 2-bromo-3,4,6-trichloro, 6-fluoro-2,4,5-trichloro, 6- chloro-2,4,5-tribromo, 6-fluoro-2,4,5-tribromo, 2-bromo-3,4,6-trifluoro, 2-chloro- 3,4,6-trifluoro, 6-methyl-2,4,5-trichloro, 6-methyl-2,4,5-tribromo, 6-methyl-2,4,5- trifluoro, 6-(trifluoromethyl)-2,4,5-trichloro, 6-(trifluoromethyl)-2,4,5-tribromo, 2- (trifluoro-methyl)-3,4,6-trifluoro, 6-(trifluoromethoxy)-2,4,5-tribromo, 2- (trifluoromethoxy)-3,4,6-trifluoro, 6-(trifluoromethoxy)-2,4,5-trichloro, 2-bromo- 3,5,6-trichloro, 6-fluoro-2,3,5-trichloro, 6-chloro-2,3,5-tribromo, 6-fruoro-2,3,5- tribromo, 2-bromo-3,5,6-trifluoro, 2-chloro-3,5,6-trifluoro, 6-methyl-2,3,5- trichloro, 6-methyl-2,3,5-tribromo, 2-methyl-3,5,6-trifluoro, 6-(trifluoromethyl)- 2,3,5-trichloro, 6-(trifluoro-methyl)-2,3,5-tribromo, 2-(trifluoromethyl)-3,5,6- trifluoro , 2- (trifluoromethoxy) -3,5, 6-trichloro , 6- (trifluoromethoxy) -2,3,5- tribromo, 2-(trifluoromethoxy)-3,5,6-trifluoro, 4-bromo-2,3,5,6-tetrachloro, 4- fluoro-2,3,5,6-tetrachloro,4-chloro-2,3,5,6-tetrabromo-, 4-fluoro-2, 3,5,6- tetrabromo, 4-chloro-2,3,5,6-tetrafluoro, 4-bromo-2,3,5,6-tetrafluoro, 2-bromo- 3,4,5,6-tetrachloro, 6-fluoro-2,3,4,5-tetrachloro-, 2-chloro-3,4,5,6-tetrafluoro, 2- bromo-3,4,5,6-tetrafluoro, 2-chloro-3,4,5,6-tetrabromo, 2-fluoro-3, 4,5,6- tetrabromo, 4-methyl-2,3,5,6-tetrachloro, 4-methyl-2,3,5,6-tetrabromo, 4-methyl- 2,3,5,6-tetrafluoro, 2,3,5,6-tetrachloro-4-(trifluoromethyl), 2,3,5,6-tetrabromo-4- (trifluoromethyl), 2,3,5,6-tetrafluoro-4-(trifluoromethyl), 2,3,5,6-tetrachloro-4- (trifluoromethoxy), 2,3,5,6-tetrabromo-4-(trifluoromethoxy, 2,3,5,6-tetrafluoro-4- (trifluoromethoxy), 6-methyl-2,3,4,5-tetrachloro, 6-methyl-2,3,4,5-tetrabromo, 2- methyl-3,4,5,6-tetrafluoro, 2,3,4,5-tetrachloro-6-(trifluoromethyl), 2,3,4,5- tetrabromo-6-(trifluoromethyl), 3,4,5,6-tetrafluoro-2-(trifluoromethyl), 2,3,4,5- tetrachloro-6-(trifluoromethoxy), 2,3,4,5-tetrabromo-6-(trifluoromethoxy), and 3 , 4, 5 , 6-tetr afluoro2 - (trifluoromethoxy) . The term heterocyclic refers to a substituted 6 membered unsaturated ring selected from 3- or 4-pyridinyl, 5-pyrimidinyl, 3-pyridazinyl or a 5 membered unsaturated ring selected from 3-thienyl, 3-furyl, 3-pyrrolyl, 4- isoxazolyl, 4-isothiazolyl or 4-pyrazolyl wherein both the positions on the heterocyclic ring adjacent to the bond to the cyclopropyl ring are substituted and the ring is substituted with from 2 to 4 substituents independently selected from (C j -C^ alkyl, (C 3 -C 6 )cycloalkyl, trihalomethyl, trihalomethoxy, halogen, cyano, (C^C^alkoxycarbonyl, nitro, phenyl, and phenoxy. The term heterocyclic also refers to a substituted or unsubstituted 6 membered unsaturated ring containing one, two or three heteroatoms, preferably one, two or three heteroatoms independently selected from oxygen, nitrogen, and sulfur or a 5 membered unsaturated ring containing one, two or three heteroatoms, preferably one or two heteroatoms independently selected from oxygen, nitrogen, and sulfur wherein the heterocyclic ring is unsubstituted or is substituted with from 1 to 3 substituents wherein at least one of the positions of the heterocyclic ring adjacent to the bond to the cyclopropyl ring is a hydrogen substituent. Examples of heterocycles include but are not limited to 2-, 3- or 4-pyridinyl, pyrazinyl, 4-, or 5-pyrimidinyl, pyridazinyl, pyrazole, imidazolyl, 2 or 3-thienyl, 2 or 3-furyl, 3-pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl. These rings may be optionally substituted with up from 1 to 3 substituents independently selected from (C 1 -C 4 ) alkyl, (C 3 -C 7 )cycloalkyl, trihalomethyl, halogen, cyano, (C 1 -C 4 )alkoxycarbonyl, nitro, phenyl, and phenoxy. Halogen or halo includes iodo, fluoro, bromo and chloro moieties. The compounds of the general Formula I may be obtained in preparation as E/Z isomeric mixtures. These isomers can be separated into individual components by conventional means. The substituted cyclopropanes of Formula I may be obtained in preparation as cis and trans isomeric mixtures which can also be separated into individual components by conventional means. Both the individual isomeric compounds as well as mixtures thereof form subjects of the invention and can be used as fungicides and insecticides. One preferred embodiment of this invention includes the compounds, enantiomorphs, salts and complexes of Formula I wherein X is CH or N; Z is O or NH; A, R 3 , R 4 , and R 5 are each hydrogen; R x and R 2 are CH 3 ; R 7 is 2,6- dichlorophenyl or 2,6-difluorophenyl; and R 6 is hydrogen. Another preferred embodiment of this invention includes the compounds, enantiomorphs, salts and complexes of Formula I wherein X is CH or N; Z is O or NH; A, R 3 , R 4 , and R 5 are each hydrogen; R x and R 2 are CH 3 ; R 7 is 2,6- dichlorophenyl or 2,6-difluorophenyl; and R 6 is halo, (C 1 -C 4 )alkyl, halo(C 1 - C )alkyl, cyclopropyl, halocyclopropyl, (C 2 -C 4 )alkenyl, halo(C 2 -C 4 )alkenyl, (C 2 - C 4 )alkynyl, or halo(C 2 -C 4 )alkynyl. Another preferred embodiment of this invention is the compounds, enantiomorphs, salts and complexes of Formula I wherein X is CH or N; Z is O or NH; A is hydrogen; R j and R 2 are independently (C 1 -C 4 )alkyl; R 3 , R 4 , and R 5 are hydrogen; R 7 is phenyl other than 2,6-dichlorophenyl or 2,6-difluorophenyl such that the positions on the phenyl ring adjacent to the bond to the cyclopropyl rings are both substituted, and R 6 is selected from hydrogen, halo, (C^C^alkyl, halo(C 1 -C 4 )alkyl, cyclopropyl, halocyclopropyl, (C 2 -C 4 )alkenyl, halo (C 2 -C ) alkenyl, (C 2 -C 4 )alkynyl, and halo(C 2 -C 4 )aιkynyl. A more preferred embodiment of this invention is the compounds, enantiomorphs, salts and complexes of Formula I wherein X is CH or N; Z is O or NH; A is hydrogen; R x and R 2 are independently (C^C^ alkyl; R 3 , R 4 and R 5 are hydrogen; R 6 is hydrogen; and R 7 is 2,3,6-trisubstitutedphenyl, 2,4,6- trisubstitutedphenyl, 2,3,4,6-tetrasubstitutedphenyl, 2,3,5,6-tetrasubstituted, or 2, 3,4, 5,6-pentasubstitutedphenyl. An even more preferred embodiment of this invention are the compounds, enantiomorphs, salts and complexes of Formula I wherein X is N; Z is NH; A is hydrogen; R : and R 2 are CH 3 ; R 3 , R 4 and R 5 are hydrogen; R 6 is hydrogen; and R 7 is 2,3,6-trihalophenyl, 2,4,6-trihalophenyl, 2,3,4,6-tetrahalophenyl, 2,3,5,6- tetrahalophenyl, or 2,3,4,5,6-pentahalophenyl. Still another preferred embodiment of this invention is the compounds, enantiomorphs, salts and complexes of Formula I wherein X is CH or N; Z is O or NH; A is hydrogen; R x and R 2 are independently (C 1 -C 4 )alkyl; R 3 , R 4 and R 5 are hydrogen; R 7 is a substituted or unsubstituted phenyl or heterocyclic wherein at least one of the positions on the phenyl or heterocyclic ring adjacent to the bond to the cyclopropyl ring is a hydrogen substituent; and R 6 is (C 1 -C 4 )alkyl, halo(C 1 - C 4 )alkyl, cyclopropyl, halocyclopropyl, (C 2 -C 4 )alkenyl, halo (C 2 -C 4 ) alkenyl, (C 2 - C 4 )alkynyl, halo(C 2 -C 4 )alkynyl, halo or cyano. Another more preferred embodiment of this invention is the compounds, enantiomorphs, salts and complexes of Formula I wherein X is N; Z is O or NH; A is hydrogen; x and R 2 is (CH 3 ); R 3 , R 4 and R 5 are hydrogen; R 7 is phenyl, 2- substitutedphenyl, 3-substitutedphenyl, 4-substitutedphenyl, 2,3- disubstitutedphenyl 2,4-disubstitutedphenyl, 2,5-disubstitutedphenyl, 3,4- disubstitutedphenyl, 3,5-disubstituted, 2,3,4-trisubstitutedphenyl, 2,3,5- trisubstitutedphenyl, 2,4,5-trisubstitutedphenyl, 3,4,5-trisubstitutedphenyl, or 2,3,4,5-tetrasubstitutedphenyl; and R 6 is halo, cyano, (C 1 -C 4 )alkyl, or halo(C 1 - C 4 )alkyl. A second even more preferred embodiment of this invention is the compounds, enantiomorphs, salts and complexes of Formula II wherein R 7 is phenyl, 2-halophenyl, 3-halophenyl, 4-halophenyl, 2,3-dihalophenyl 2,4- dihalophenyl, 2,5-dihalophenyl, 3,4-dihalophenyl, 3,5-dihalophenyl, 2,3,4- trihalophenyl, 2,3,5-trihalophenyl, 2,4,5-trihalophenyl, 3,4,5-trihalophenyl, or 2,3,4,5-tetrahalophenyl, and R 6 is (C 1 -C 4 )alkyl. II A most preferred embodiment of this invention is the compounds, enantiomorphs, salts and complexes of Formula II wherein R 7 is phenyl, 2- chlorophenyl, 3-chlorophenyl, or 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-dichlorophenyl, 2,4-difluorophenyl, 2-chloro-4-fluorophenyl, 2-fluoro-4-chlorophenyl, and R 6 is CH 3 . Typical compounds of Formula I encompassed by the present invention wherein A, R 3 , R , and R 5 are hydrogen; X is CH and Z is O; and R x is methyl include those compounds presented in Table 1 of Formula III where R 2 , R 6 , and R 7 are defined in Table 1. As used in Tables 1 to 12, Ph is phenyl. Formula III Table 1 1.38 CH, CH, 2,3,5-Cl(Ph) 1.39 CH, CH, 2,3-F(Ph) -^ σ σ σϊ σ σ> σ <j> ϊ C i oι <^ & i ϋi <χ σi w Φ± ^ t ^ t^ φ ^ ^ OD -j σi σi ^ o o i-' o cD oo ^i σi oi - ύ i-i o o * x ι tΛ CT^ ω M θCD ∞ ^ σ5 CT rf- ω w ι-' θ ∞ ισ5 θι ^ ω bo ι-'θ ΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩ -0 0 :0 :0 c o cα o- co -o -o O H U α. co eo co co eo o o co o o co o co co co co eO eO W eO CO CO CO M CO CO eO CO CO OO CO CO CO W CO M M K ^* * π^ ^™l π^ ^**rf IT"! ^^ * ^ > ^ T * T * ^^ ^"^ ^rf πrt ^rt ^^ ^™l π™l tτ"l *rt ^^ ^"^ ^^ ^ " ^^ ^ > * ^ ^^ fT"i "l^ ^^ ^"^ ^"""rt ^^ T " ^^ ^^ ("'["i iH ^1 * " ^ ^ * ^^ T^ ^^ o o ooooooooooooooooooooooooooooooooooooooooooooo o o 6 i 6666 i i i i i o oo oooooo d 0 d 0 d d . 2 . 2 . s . 2 .« . 2 .«, .«, .«, .g .«, rr. r-i ^ M m τ * ιn m N m m O H N C * * ιO D t- OO C O H N O '* * -. C * X) σ) O H N m ^ ιO "X) l (» " GU * > " CΛ S ffl κ^ Sra ram om3 Sθ3 a^ mm mo) O H H O O O H O O ri H O O ri O H H → τ H H H H H H H H H H rH τ H H τH C H C H I C C * l I C^ TH I— I i— I TH I— I ΓH IH I— I H H H rH TH i— I TH i— I i— I i— I i— I i— I i— I i—l i— I O H U α. O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O 90 90 ^ oo m o H i co ^ ιo o ι> ∞ a o H iN n ^ * - ι ι t * » σ5 θ H ( co * ^ ιo co ι ∞ ffi θ H (N n M M M ** * * ^ ** '* * * ^ '* ^ ^ * 0 '0 * 0 * Λ * Λ * Λ l-. lύ * fi lO "I5 tD CD (D ^ rH τH rH τ→ ι→ rH ι→ τH τH τH ι-H τH ιH ι→ rH rH τH τH rH rH rH rH rH rH rH τH rH rH τ→ H τH τH ιH rH ^ rH H rH τH rH rH H rH rH rH τH ι→ ι→ ι→ ι→ rH rH rH H r-. rH r-. 1.186 CH 3 n-C 3 H 7 4-NO 2 (Ph) 1.187 CH 3 n-C 3 H 7 2,4-Cl(Ph) 1.188 CH 3 n-C 3 H 7 2,4-F(Ph) 1.189 CH 3 iso-C 3 H7 Ph 1.190 CH 3 iso-C 3 H 7 4-Cl(Ph) 1.191 CH 3 n-C 4 H 9 Ph 1.192 CH 3 n-C 4 H9 4-Cl(Ph) 1.194 CH 3 iso-C 4 H9 4-Cl(Ph) 1.196 CN n-C 3 H 7 Ph 1.201 CF 3 n-C 3 H 7 Ph 1.203 CF 3 n-C 4 H 9 Ph 1.205 H CF 3 Ph 1.206 CHs CF 3 Ph 1.207 CN CF 3 Ph 1.208 CF 3 CF 3 Ph 1.212 CF 3 CH 2 =CH Ph 1.213 H CH 3 CH=CH Ph 1.214 CH 3 CH 3 CH=CH Ph 1.215 CN CH 3 CH=CH Ph 1.216 CF 3 CH 3 CH=CH Ph 1.217 CH 3 CH 3 2-Cl,4-F(Ph) Table 2: Compounds 2.1 to 2.217 are compounds of Formula I wherein A, R 3 , R 4 , and R 5 are hydrogen; X is N and Z is O; R x is methyl; and R 2 , R 6 , and R 7 are defined as in Table 1. The following compounds are all oils and possess either a trans cyclopropane or an enriched trans cyclopropane stereochemistry for R7 and the iminoxy substituent, and the indicated A:B iminoxy isomer ratio is shown: 2.11, 2.12 (9:1 A:B isomers), 2.14A (7:3 trans:cis cyclopropane isomers), 2.17 (9:1 A:B isomers), 2.18A, 2.20 (4:1 A:B isomers), 2.20B, 2.34 (5:1 A:B isomers), 2.166 (4:1 A:B isomers), 2.170 (6:1 A:B isomers), 2.178 (4:1 A:B isomers), 2.189 (7:3 A:B isomers), and 2.217 (6:1 A:B isomers). Table 3: Compounds 3.1 to 3.217 are compounds of Formula I wherein A, R 3 , R 4 , and R 5 are hydrogen; X is N and Z is NH, - L is methyl; and R 2 , R 6 , and R 7 are defined as in Table 1. The following compouns possess either a trans cyclopropane or an enriched trans cyclopropane stereochemistry for R7 and the iminoxy substituent, and the indicated A:B iminocy isomer ratio is shown: 3.11 (oil, 4:1 A:B isomers), 3.12A (mp. 100-103 °C), 3.14A (oil, 7:3 trans is cyclopropane isomers), 3.17 (oil, 9:1 A:B isomers), 3.18A (mp. 95-99 °C), 3.20 (oil, 4:1 A:B isomers), 3.20A (mp. 57-61 °C), 3.20B (oil), 3.34A (mp. 121-125 °C), 3.40A (oil), 3.166 (oil, 4:1 A:B isomers), 3.170A (mp. 74-77 °C), 3.178 (oil, 4:1 A:B isomers), 3.189 (oil, 7:3 A:B isomers), and 3.217A (mp 110-113 °C). Typical compounds of Formula I encompassed by the present invention wherein A, R 3 , R 4 , and R 5 are hydrogen; X is CH and Z is O; and R x is methyl include those compounds presented in Table 4 of Formula III where R 2 , R 6 , and R 7 are defined in Table 4. Formula III Table 4 4.1 H CH 3 2-pyridyl 4.2 H CH, 3-pyridyl 4.3 H CH, 4-pyridyl 4.4 H CH, 2-pyrazinyl 4.5 H CH, 4-pyrimidinyl 4.6 H CH, 5-pyrimidinyl 4.1 H CH, 3-pyridazinyl 4.8 H CH, 4-pyridazinyl 4.9 H CH, 2-furyl 4.10 H CH, 3-furyl 4.11 H CH, 2-thienyl 4.12 H CH, 3-thienyl 4.13 CH, CH, 2-pyridyl 4.14 CH, CH, 3-pyridyl 4.15 CH, CH, 4-pyridyl P PPPPP Ω Ω Ω OΩΩΩΩΩΩΩΩΩΩΩ CH OK O v OI O in oi * Λ "Λ * Λ W - » » W » W » M » » W -O W M » W » Ω mΩ*ΗΩ HHΩ HHΩ '"T"'Ω HH Ω HH Ω HH Ω HH Ω i™HΩ ' ■■ H Ω Hπ W IH IH IH IH K Λ |J |i < |J → HH 4.65 iso-C 3 H 7 CH, 2-pyridyl 4.66 iso-C 3 H 7 CH, 3-pyridyl 4.67 iso-C 3 H 7 CH, 4-pyridyl 4.68 iso-C 3 H 7 CH, 2-furyl 4.69 iso-C 3 H 7 CH, 3-furyl 4.70 iso-C 3 H CH, 2-thienyl 4.71 iso-C 3 H 7 CH, 3-thienyl 4.72 n-C 4 H9 CH, 2-pyridyl 4.73 n-C 4 H 9 CH, 3-pyridyl 4.74 n-C 4 H 9 CH, 4-pyridyl 4.75 -C 4 H9 CH, 2-furyl 4.76 n-C 4 H 9 CH, 3-furyl 4.77 n-C 4 H 9 CH, 2-thienyl 4.78 n-C 4 H 9 CH, 3-thienyl 4.79 iso-C 4 H 9 CH, 2-pyridyl 4.80 iso-C 4 H 9 CH, 3-pyridyl 4.81 iso-C 4 H 9 CH, 4-pyridyl 4.82 iso-C 4 H 9 CH, 2-furyl 4.83 iso-C 4 H 9 CH, 3-furyl 4.84 iso-C 4 H 9 CH, 2-thienyl 4.85 iso-C 4 H9 CH 3 3-thienyl 4.86 c-CsHs CH 3 2-pyridyl 4.87 c-C 3 Hδ CH 3 3-pyridyl 4.88 c-C 3 H 5 CH 3 4-pyridyl 4.89 c-C 3 H5 CH 3 2-furyl 4.90 c-C 3 Hδ CHs 3-furyl 4.91 c-C 3 H5 CH 3 2-thienyl 4.92 c-C 3 Hδ CHs 3-thienyl 4.93 CN CHs 2-pyridyl 4.94 CN CHs 3-pyridyl 4.95 CN CHs 4-pyridyl 4.96 CN CHs 2-furyl 4.97 CN CH 3 3-furyl 4.98 CN CHs 2-thienyl 4.99 CN CHs 3-thienyl 4.100 CF 3 CHs 2-pyridyl 4.101 CF 3 CHs 3-pyridyl 4.102 CF 3 CHs 4-pyridyl 4.105 CF 3 CHs 2-thienyl 4.106 CF 3 CHs 3-thienyl 4.107 CH 3 C2H5 2-pyridyl 4.108 CH 3 C2H5 3-pyridyl 4.109 CH 3 C 2 H 5 4-pyridyl 4.110 CH 3 C2H5 2-furyl 4.111 CH 3 C2H5 3-furyl 4.112 CH 3 C2H5 2-thienyl 4.113 CH 3 C2H5 3-thienyl 4.114 CH 3 n-C 3 H 7 2-pyridyl 4.115 CH 3 n-CsH 7 3-pyridyl tP--. μ] * ^. 4 °& - 1 4^ ■ * > - H≥ > - rf»- ι4i » . -^ H 5 *- f^ !^ *P*- H^ H^ >^- f^- H^ t^" i^' " 5 *- i^- tf^ "*» ■ * ^- >ls » . " ^- H^- -4^- H^ t^ j* 5 *" I* 58 ' t^ l^ 5 " ϊ^ 4 " H 5 *" I* 5 *" l 1 **" t*^ l^*- 1^ t 1 ^ l^ 1 " 1^" t 1 H-i I— i H^ H" 1 H ™ 1 H"-*-* I ' H- 1 H " -** I ' ι ' |— — ι ι ' ι ■ ^-i i ■ i ■ ι_ι ι ■ ι > _ι μ μ μ H μ μ H' H' Hi μ μ H μ i-i CΛ OT σi oi ϋi O cπ σi C7» h| ** -. ^ ^ ^ >^ ^ ^ > ^ ^ - C C CO C CO CO CO C CO C CO ω ω c to t b t t M KJ H μ μ oo -j σi cπ μi- t i-' o o oo ι m ϋi H\ ω M H θ cD Qo ι σ) σι ^ σ5 OT ιf*. ω ι>3 !- J O D 00 0 01 * 1 * CO t I-' O D OO ] 0 ΩΩΩΩΩΩΩΩΩΩΩΩΩΩOΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩΩ b o - K-T 1 co to et- S±-, C iO t iO £f πf p * . * H". p P CD B p VJ_VJ VJ VJ * — Table 5: Compounds 5.1 to 5.158 are compounds of Formula I wherein A, R 3 , R 4 , and R 5 are hydrogen; X is N and Z is O; R x is methyl; and R 2 , R 6 , and R 7 are defined as in Table 4. Table 6: Compounds 6.1 to 6.158 are compounds of Formula I wherein A, R 3 , R 4 , and R 5 are hydrogen; X is N and Z is NH, R x is methyl; and R 2 , R 6 , and R 7 are defined as in Table 4. Typical compounds of Formula I encompassed by the present invention wherein A, R 3 , R 4 , and R 5 are hydrogen; X is CH and Z is O; and R : is methyl include those compounds presented in Table 7 of Formula III where R 2 , R 6 , and R 7 are defined in Table 7 Formula III Table 7 7.23 CH, H 2,3,6-F(Ph) 7.24 CH, H 2,4,6-F(Ph) 7.25 CH, H 2.6-CH 3 (Ph) 7.26 CH, H 2,3,6-CH 3 (Ph) 7.27 CH, H 2,4,6-CH 3 (Ph) 7.28 CH, H 2,6-CH 3 O(Ph) 7.29 CH, H 2,3,6-CH 3 O(Ph) 7.30 CH, H 2,4,6-CH 3 O(Ph) 7.31 CH, H 2,6-NO (Ph) 7.32 CH, H 2,6-CN(Ph) 7.33 CH, H 2,3,6-CN(Ph) 7.34 CH, H 2,4,6-CN(Ph) 7.35 CH, H 2,6-Ph(Ph) 7.36 CH, H 2,3,6-PhPh) 7.37 CH, H 2,4,6-Ph(Ph) 7.38 CH, H 2,6-PhO(Ph) 7.39 CH, H 2,3,6-PhO(Ph) 7.40 CH, H 2,4,6-PhO(Ph) 7.41 CH, H 2,6-CF,(Ph) 7.42 CH, H 2 ) 3,6-CF,(Ph) 7.43 CH, H 2,4,6-CF,(Ph) 7.44 CH, H 2,6-CF,O(Ph) 7.45 CH, H 2,3,6-CF,O(Ph) 7.46 CH, H 2,4,6-CF,O(Ph) 7.47 CH, H 2,3,4,6-Cl(Ph) 7.48 CH, H 2,3,5,6-Cl(Ph) 7.49 CH, H 2,3,4,5,6-Cl(Ph) 7.50 CH, H 2,3,4,6-Ph(Ph) 7.51 CH, H 2,3,5,6- Ph(Ph) 7.52 CH, H 2,3,4,5,6- Ph(Ph) 7.53 CH, H 2,3,4,6-PhO(Ph) 7.54 CH, H 2,3,5,6- PhO(Ph) 7.55 CH, H 2,3 J 4,5,6-PhO(Ph) 7.56 CH, H 2,3,4,6-Br(Ph) 7.57 CH, H 2,3,5,6-Br(Ph) 7.58 CH, H 2,3,4,5,6-Br(Ph) 7.59 CH, H 2,3,4,6-F(Ph) 7.60 CH, H 2,3,5,6-F(Ph) 7.61 CH, H 2,3,4,5,6-F(Ph) 7.62 CH, H 2,3 ; 4,6-CH,(Ph) 7.63 CH, H 2,3,5,6-CH,(Ph) 7.64 CH, H 2,3,4,5,6-CH,(Ph) 7.65 CH, H 2,3,4,6-C2H5(Ph) 7.66 CH, H 2,3,5,6- C 2 H 5 (Ph) 7.67 CH, H 2,3,4,5,6- C 2 H 5 (Ph) 7.68 CH, H 2,3,4,6-CH,O(Ph) 7.69 CH, H 2,3,5,6-CH,O(Ph) 7.70 CH, H 2,3,4,5,6-CH,O(Ph) 7.71 CH, H 2,3,4,6-CF,(Ph) 1.12 CH, H 2,3,5,6-CF,(Ph) 1.13 CH, H 2,3,4,5,6-CF,(Ph) 1.14 CH, H 2,3,4,6-CF,O(Ph) 1.15 CH, H 2,3,5,6-CF,O(Ph) 1.16 CH, H 2,3,4,5,6-CF,O(Ph) 7.77 CH, H 2,3,4,6-CN(Ph) 7.78 CH, H 2,3,5,6-CN(Ph) 7.79 CH, H 2,3,4,5,6-CN(Ph) 7.80 CH, H 2-Br-6-Cl(Ph) 7.81 CH, H 2-Br-6-F(Ph) 7.82 CH, H 2-Br-6-CH,(Ph) 7.83 CH, H 2-Br-6-CF,(Ph) 7.84 CH, H 2-Br-6-CH,O(Ph) 7.85 CH, H 2-Br-6-CF,O(Ph) 7.86 CH, H 2-Br-6-CN(Ph) 7.87 CH, H 2-Cl-6-F(Ph) 7.88 CH, H 2-Cl-6-CH,(Ph) 7.89 CH, H 2-Cl-6-CF,(Ph) 7.90 CH, H 2-Cl-6-CH,O(Ph) 7.91 CH, H 2-Cl-6-CF,O(Ph) 7.92 CH, H 2-Cl-6-CN(Ph) 7.93 CH, H 2-F-6-CH,(Ph) 7.94 CH, H 2-F-6-CF,(Ph) 7.95 CH, H 2-F-6-CH,O(Ph) 7.96 CH, H 2-F-6-CF,O(Ph) 7.97 CH, H 6-CN-2F(Ph) 7.98 CH, H 2-CH,-6-CF,(Ph) 7.99 CH, H 6-CH,O-2-CH,(Ph) 7.100 CH, H 2-CH,-6-CF,O(Ph) 7.101 CH, H 6-CN-2-OCH 3 (Ph) 7.102 CH, H 6-CN-2-CH,(Ph) 7.103 CH, H 3,6-Cl-2-F(Ph) 7.104 CH, H 3Cl-2,6-F(Ph) 7.105 CH, H 4-Cl-2,6-F(Ph) 7.106 CH, H 2-Br-3,6-Cl(Ph) 7.107 CH, H 2,3-Br-6-Cl(Ph) 7.108 CH, H 3-Cl-2,6Br(Ph) 7.109 CH, H 2,6-Cl-3-F(Ph) 7.110 CH, H 2,3-Cl-6-F(Ph) 7.111 CH, H 2-Cl-3,6-F(Ph) 7.112 CH, H 3-Br-2,6-Cl(Ph) 7.113 CH, H 3-Br-2,6-F(Ph) 7.114 CH, H 3-Br-6Cl-2-F(Ph) 7.115 CH, H 2-Br-5Cl-6-F(Ph) 7.116 CH, H 2,6-Br-3-F(Ph) 7.117 CH, H 2,5-Br-6-F(Ph) 7.118 CH, H 2,4-Cl-6F(Ph) 7.119 CH, H 2,6-Cl-4F(Ph) 7.120 CH, H 2,4-Cl-6Br(Ph) 7.121 CH, H 2,6-Cl-4Br(Ph) 7.122 CH, H 2,4-F-6-Cl(Ph) 7.123 CH, H 2,4-F-6-Br(Ph) 7.124 CH, H 2,6-F-4-Br(Ph) 7.125 CH, H 2,4-Br-6-F(Ph) 7.126 CH, H 2,4-Br-6-Cl(Ph) 7.127 CH, H 2,6-Br-4-Cl(Ph) 7.128 CH, H 2,6-Br-4-F(Ph) 7.129 CH, H 2,4-Cl-6-CH,(Ph) 7.130 CH, H 2,6-Cl-4-CH,(Ph) 7.131 CH, H 2-Cl-4,6-(CH,) ? (Ph) 7.132 CH, H 4-Cl-2,6-(CH,) 9, (Ph) 7.133 CH, H 2,4-F-6-CH,(Ph) 7.134 CH, H 2,6-F-4-CH,(Ph) 7.135 CH, H 2-F-4,6-(CH,) ? (Ph) 7.136 CH, H 4-F-2,6-(CH,),(Ph) 7.137 CH, H 2,4-Br-6-CH,(Ph) 7.138 CH, H 2,6-Br-4-CH,(Ph) 7.139 CH, H 2-Br-4,6-(CH,) ϊ JPh) 7.140 CH, H 4-Br-2,6-(CH,) ? (Ph) 7.141 CH, H 2,4-Cl-6-CF,(Ph) 7.142 CH, H 2,6-Cl-4-CF,(Ph) 7.143 CH, H 2-Cl-4,6-(CF,) ? (Ph) 7.144 CH, H 4-Cl-2,6-(CF,) 9 (Ph) 7.145 CH, H 2,4-F-6-CF,(Ph) 7.146 CH, H 2,6-F-4-CF,(Ph) 7.147 CH, H 2-F-3,6-(CF,),(Ph) 7.148 CH, H 3-F-2,6-(CF,) ? (Ph) 7.149 CH, H 2,3-Br-6-CF,(Ph) 7.150 CH, H 2,6-Br-3-CF,(Ph) 7.137 CH, H 2-Br-4,6-(CF,) ? (Ph) 7.138 CH, H 4-Br-2,6-(CF,) ? (Ph) 7.139 CH, H 2,4-Cl-6-CF,O(Ph) 7.140 CH, H 2,6-Cl-4-CF,O(Ph) 7.141 CH, H 2-Cl-4,6-(CF,O) ? (Ph) 7.142 CH, H 4-Cl-2,6-(CF,O) ? (Ph) 7.143 CH, H 2,4-F-6-CF,O(Ph) 7.144 CH, H 2,6-F-4-CF,O(Ph) 7.145 CH, H 2-F-4,6-(CF,O) ? (Ph) 7.146 CH, H 4-F-2,6-(CF,O) ?, (Ph) 7.147 CH, H 2,4-F-6-CF,O(Ph) 7.148 CH, H 2,6-F-4-CF,O(Ph) 7.149 CH, H 2-F-4,6-(CF,O) ? (Ph) 7.150 CH, H 4-F-2,6-(CF,O) ? (Ph) 7.151 CH, H 2-Br-3,4,6-Cl(Ph) 7.152 CH, H 6-F-2,4 ; 5-Cl(Ph) 7.153 CH, H 6-Cl-2,4,5-Br(Ph) 7.154 CH, H 6-F-2,4,5-Br(Ph) 7.155 CH, H 2-Br-3,4,6-F(Ph) 7.156 CH, H 2-Cl-3,4,6-F(Ph) 7.157 CH, H 6-CH,-2,4,5-Cl(Ph) 7.158 CH, H 6-CH,-2,4,5-Br(Ph) 7.159 CH, H 6-CH,-2,4,5-F(Ph) 7.160 CH, H 6-CF a -2,4,5-Cl(Ph) 7.161 CH, H 6-CF,-2,4,5-Br(Ph) 7.162 CH, H 6-CF,-2,4.5-F(Ph) 7.163 CH, H 6-CF,O-2,4,5-Cl(Ph) 7.164 CH, H 6-CF,O-2,4,5-Br(Ph) 7.165 CH, H 6-CF,O-2,4,5-F(Ph) 7.166 CH, H 2-Br-3,5,6-Cl(Ph) 7.167 CH, H 2-Br-3,5,6-F(Ph) 7.168 CH, H 2-Cl-3,5,6-F(Ph) 7.169 CH, H 6-F-2,3,5-Cl(Ph) 7.170 CH, H 6-Cl-2,3,5-Br(Ph) 7.171 CH, H 6-F-2,3,5-Br(Ph) 7.172 CH, H 6-CH,-2,3,5-Cl(Ph) 7.173 CH, H 6-CH,-2,3,5-Br(Ph) 7.174 CH, H 2-CH,-3,5,6-F(Ph) 7.175 CH, H 6-CF,-2,3,5-Cl(Ph) 7.176 CH, H 6-CF,-2,3,5-Br(Ph) 7.177 CH, H 2-CF,-3,5,6-F(Ph) 7.178 CH, H 6-CF,O-2,3,5-Cl(Ph) 7.179 CH, H 6-CF,O-2,3,5-Br(Ph) 7.180 CH, H 2-CF,O-3,5,6-F(Ph) 7.172 CH, H 4-Br-2,3,5,6-Cl(Ph) 7.173 CH, H 4-F-2,3,5,6-Cl(Ph) 7.174 CH, H 4-Cl-2,3,5,6-Br(Ph) 7.175 CH, H 4-F-2,3,5,6-Br(Ph) 7.176 CH, H 4-Cl-2,3,5,6-FPh) 7.177 CH, H 4-Br-2,3,5,6-F(Ph) 7.178 CH, H 2-Br-3,4,5 ; 6-Cl(Ph) 7.179 CH, H 2-F-3,4,5,6-Cl(Ph) 7.180 CH, H 2-Cl-3,4,5,6-F(Ph) 7.181 CH, H 2-Br-3,4,5,6-F(Ph) 7.182 CH, H 6-Cl-2,3,4,5-Br(Ph) 7.183 CH, H 6-F-2 ) 3,4,5-Br(Ph) 7.184 CH, H 4-CH,-2,3,5,6-Cl(Ph) 7.185 CH, H 4-CH,-2,3,5,6-Br(Ph) 7.186 CH, H 4-CH,-2,3 ) 5,6-F(Ph) 7.187 CH, H 4-CF,-2,3,5,6-Cl(Ph) 7.188 CH, H 4-CF,-2,3,5,6-Br(Ph) 7.189 CH, H 4-CF,-2,3 ; 5,6-F(Ph) 7.190 CH, H 4-CH,o-2,3,5,6-Cl(Ph) 7.191 CH, H 4-CF,O -2,3,5,6-Br(Ph) 7.192 CH, H 4-CF,O-2,3 ; 5,6-F(Ph) 7.193 CH, H 4-CF,O-2,3,5,6-Cl(Ph) 7.194 CH, H 6-CH,-2,3,4 ) 5-Cl(Ph) 7.195 CH, H 6-CH,-2,3,4,5-BrPh) 7.196 CH, H 2-CH,-3,4,5,6-F(Ph) 7.197 CH, H 6-CF,O-2,3,4,5-Cl(Ph) 7.198 CH, H 6-CF,O-2,3,4,5-BrPh) 7.199 CH, H 2-CF,O-3,4,5,6-F(Ph) 7.200 CH, CH, 2,6-Cl(Ph) 7.201 CH, CH, 2,3,6-Cl(Ph) 7.202 CH, CH, 2,4,6-Cl(Ph) 7.203 CH, CH, 2,6-Br(Ph) 7.204 CH, CH, 2,3,6-Br(Ph) 7.205 CH, CH, 2,4,6-Br(Ph) 7.206 CH, CH, 2,6-F(Ph) 7.207 CH, CH, 2,3,6-F(Ph) 7.208 CH, CH, 2,4,6-F(Ph) 7.209 CH, CH, 2,6-CH 3 (Ph) 7.210 CH, CH, 2,3,6-CH 3 (Ph) 7.211 CH, C 2 H 5 2,4,6-CH 3 (Ph) 7.212 CH, n-C 3 H 7 2,6-Cl(Ph) 7.213 CH, iso-C 3 H 2,3,6-Cl(Ph) 7.214 CH, n-C 4 H 9 2,4,6-Cl(Ph) 7.215 CH, iso-C 4 H9 2,6-Cl(Ph) 7.216 CH, CH 2 — CH 2,3,6-Cl(Ph) 7.217 CH, CH 3 CH=CH 2,4,6-Cl(Ph) 7.218 CN H 2,6-Cl(Ph) 7.219 CN CH, 2.3,6-Cl(Ph) 7.220 CN C2H5 2,4,6-Cl(Ph) 7.221 CN n-C 3 H 7 2,6-Cl(Ph) 7.222 CN iso-C 3 H 2,3,6-Cl(Ph) 7.223 CN n-C 4 H 9 2,4,6-Cl(Ph) 7.224 CN iso-C4H 9 2,6-Cl(Ph) 7.225 CN CH 2 — CH 2,3,6-Cl(Ph) 7.226 CN CH 3 CH=CH 2,4,6-Cl(Ph) 7.227 CF, H 2,6-Cl(Ph) 7.228 CF, CH, 2,3,6-Cl(Ph) 7.229 CF, C 2 Hg 2,4,6-Cl(Ph) 7.230 CF, n-C 3 H 7 2,6-Cl(Ph) 7.231 CF, iso-CsH 7 2,3,6-Cl(Ph) Table 8: Compounds 8.1 to 8.231 are compounds of Formula I wherein A, R 3 , R 4 , and R 5 are hydrogen; X is N and Z is O; R x is methyl; and R 2 , R 6 , and R 7 are defined as in Table 7. The following compounds possess either a trans cyclopropane or an enriched trans cyclopropane stereochemistry for R and the iminoxy substituent, and the indicated A:B iminoxy isomer ratio is shown: 8.16 (oil, 9:1 A:B isomers), 8.16A (oil), 8.16B (oil), 8.22 (oil, 7.9:2.1 A:B isomers), and 8.200 (oil, 4:1 A:B isomers). Table 9: Compounds 9.1 to 9.231 are compounds of Formula I wherein A, R 3 , R 4 , and R 5 are hydrogen; X is N and Z is NH, R x is methyl; and R 2 , R 6 , and R 7 are defined as in Table 7. The following compounds possess either a trans cyclopropane or an enriched trans cyclopropane stereochemistry for R 7 and the iminoxy substituent ,and the indicated A:B iminoxy isomer ratio is shown: 9.16 (oil, 9:1 A:B isomers), 9.16A (oil), 9.16B (mp. 140-146 °C), 9.22A (oil) and 9.22B (oil), and 9.200 (oil, 9:1 A:B isomers). Typical compounds of Formula I encompassed by the present invention wherein A, R 3 , R 4 , and R 5 are hydrogen; X is CH and Z is O; and Η, x is methyl include those compounds presented in Table 10 of Formula III where R 2 , R 6 , and R 7 are defined in Table 10. ormula III Table 10 10.1 H H 2,4-Cl-pyrid-3-yl 10.2 H H 2,4-F-pyrid-3-yl 10.3 H H 2-Cl-4-F-pyrid-3-yl 10.4 H H 2,4-(CH,),-pyrid-3-yl 10.5 H H 3,5-Cl-pyrid-4-yl 10.6 H H 3,5-F-pyrid-4-yl 10.7 H H 3-Cl-5-F-pyrid-4-yl 10.8 H H 3,5-(CHj a -pyrid-4-yl 10.9 H H 4, 6 - Cl-pyrimidin- 5 -yl 10.10 H H 4,6-F-pyrimidin-5-yl 10.11 H H 4,6-(CH,) 9: -pyrimidin-5-yl 10.12 H H 4-Cl-6-F-pyrimidin-5-yl 10.13 CH, H 2,4-Cl-pyrid-3-yl 10.14 CH, H 2,4-F-ρyrid-3-yl 10.15 CH, H 2-Cl-4-F-pyrid-3-yl 10.16 CH, H 2,4-(CH,),-pyrid-3-yl 10.17 CH, H 3,5-Cl-pyrid-4-yl 10.18 CH, H 3,5-F-pyrid-4-yl 10.19 CH, H 3-Cl-5-F-pyrid-4-yl 10.20 CH, H 3,5-(CH,) 5! -pyrid-4-yl o ooooo oo μo μo Hooμ μooo o p p p o p p o o p p o o p p o p p o p p p o p p o o © p p o ^j ϊ ^ σs σi ^ σs i σϊ OT cπ cπ OT OT θ Φ θo ι cΩ H ^ w ι>o *- j o o oo ---ι cΛ CJi H ^ ω o *^ o o oo ι σi OT Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω ^ HH HH HH HH HH HH HH HH HH HH HH HΓI HH _o :o -o 10.71 CH, C2H5 2,4-F-pyrid-3-yl 10.72 CH, n-C 3 H 7 2-Cl-4-F-pyrid-3-yl 10.73 CH, iso-U3H 2,4-(CH,),-pyrid-3-yl 10.74 CH, n-C-iHg 3,5-Cl-pyrid-4-yl 10.75 CH, iso-C 4 H9 3,5-F-pyrid-4-yl 10.76 CH, CH 2 =CH 3-Cl-5-F-pyrid-4-yl 10.77 CN CH 3 CH=CH 2,4-Cl-pyrid-3-yl 10.78 CN CH, 2,4-F-pyrid-3-yl 10.79 CN CH, 2-Cl-4-F-pyrid-3-yl 10.80 CN CH, 2,4-(CH,),-pyrid-3-yl 10.81 CN CH, 3,5-Cl-pyrid-4-yl 10.82 CN CH, 3,5-F-pyrid-4-yl 10.83 CN CH, 3-Cl-5-F-pyrid-4-yl 10.84 CN CH, 4,6-Cl-pyrimidin-5-yl 10.85 CN CH, 4, 6- F-pyrimidin- 5 -yl 10.86 CN CH, 2,4-Cl-thien-3-yl 10.87 CN CH, 2,4-F-thien-3-yl 10.88 CN CH, 2-Cl-4-F-thien-3-yl 10.89 CN CH, 2-F-4-Cl-thien-3-yl 10.90 CN CH, 2,4-(CH,), r thien-3-yl 10.89 CN CH, 2,4,5-Cl-thien-3-yl 10.90 CN CH, 2,4,5-F-thien-3-yl 10.91 CN CH, 2,4,5-CH,-thien-3-yl 10.92 CN C2H5 2,4-Cl-pyrid-3-yl 10.93 CN n-C 3 H 7 2,4-Cl-pyrid-3-yl 10.94 CN iso-C3H 2,4-Cl-thien-3-yl 10.95 CN n-C 4 H 9 2,4-F-thien-3-yl 10.96 CN iso-C 4 H9 2-Cl-4-F-thien-3-yl 10.97 CN CH 2 =CH 2-F-4-Cl-thien-3-yl 10.98 CN CH 3 CH=CH 2,4-(CH,)<,-thien-3-yl 10.99 CF, CH, 2,4-Cl-pyrid-3-yl 10.100 CF, CH, 2,4-F-pyrid-3-yl 10.101 CF, CH, 2,4-Cl-thien-3-yl 10.102 CF, CH, 2,4-F-thien-3-yl 10.103 CF, CH, 2-Cl-4-F-thien-3-yl 10.104 CF, CH, 2-F-4-Cl-tlιien-3-yl 10.105 CF, CH, 2,4-(CH,) 9 .-thien-3-yl 10.106 CF, CH, 3, 5- Cl-isothiazol-4-yl 10.107 CF, CH, 3,5-F-isothiazol-4-yl 10.108 CF, n-CsH-z 2,4-Cl-pyrid-3-yl 10.109 CF, iso-C3H 2,4-F-pyrid-3-yl 10.110 CF, n-C 4 H9 3,5-Cl-pyrid-4-yl 10.111 CF, iso-C 4 H9 3,5-F-pyrid-4-yl 10.112 CF, CH 2 =CH 2,4-Cl-pyrid-3-yl 10.113 CF, CH 3 CH=CH 2,4-F-pyrid-3-yl Table 11: Compounds 11.1 to 11.113 are compounds of Formula I wherein A, R 3 , R 4 , and R 5 are hydrogen; X is N and Z is O; R t is methyl; and R 2 , R 6 , and R 7 are defined as in Table 7. Table 12: Compounds 12.1 to 12.113 are compounds of Formula I wherein A, R 3 , R 4 , and R 5 are hydrogen; X is N and Z is NH, R x is methyl; and R 2 , R 6 , and R 7 are defined as in Table 7. Compounds of the present invention are prepared according to the following synthetic schemes. Scheme A describes the preparation of compounds of the Formula (I) where A and R 2 to R 7 are as defined in Tables 1-2, 4-5, 7-8, and 10-11; X is CH or N, and Z is O (compounds of Formula VI and VII). The cyclopropyl oximes (V) are reacted with the appropriately substituted benzyl derivatives (IV), where Z is a halogen, such as bromo, chloro or iodo, preferably a benzyl bromide. A cyclopropyl substituted oxime represented by the general formula (V) is treated, at room temperature, with an appropriate base to form an anion, followed by the addition of the benzyl bromide (IV). Typical bases employed are metal hydrides such as sodium hydride, alkoxides such as sodium methoxide and hydroxide bases such as sodium or potassium hydroxide and alkali bases such as sodium or potassium carbonate. Typical solvents employed with hydride bases are N,N-dimethylformamide (DMF) and tetrahydrofuran (THF); with hydroxide bases DMF, THF, methyl ethyl ketone (MEK) and acetone and with alkali bases solvents such as DMF, acetone, and MEK. As shown in Scheme A, the N-O bond in C(R2)=N-O-, appears in the E position (assuming is the larger substituent), It should be recognized that the Z isomer can also be produced as well as mixtures. When isomers are produced they are designated isomer A (higher Rf on thin layer chromatography) and isomer B (lower Rf on thin layer chromatography). The determination of which isomer, A or B possesses the E or Z geometry can be made by such conventional techniques as X ray crystallography or by spectroscopic means such as nuclear magnetic resonance spectroscopy . For the compounds of the present invention isomer A has been assigned the E iminoxy configuration and isomer B, the Z iminoxy configuration. Scheme A (IV) (V) X=CH (VI) X=N (vπ) Compounds of formula VI (X is CH) are prepared by alkylation with methyl E-α-(2-bromomethylphenyl)-β-methoxyacrylate in the presence of a base, preferably NaOH or KOH, in a solvent, preferably acetone or methyl ethyl ketone. Methyl E-α-(2-bromomethylphenyl)-β-methoxyacrylate, as a single E isomer, can be prepared in two steps from 2-methylphenylacetate as described previously in US Patent Number 4,914,128 , columns 3-4. Compounds of formula VII (X=N) are prepared by the reaction with methyl E-2- (bromomethyl)phenylglyoxylate O-methyloxime in the presence of a base, preferably NaOH or KOH, in a solvent, preferably acetone or methyl ethyl ketone. Methyl 2-(bromomethyl)phenylglyoxylate O-methyloxime can be prepared as described in US Patent Numbers 4,999,042, columns 17-18 and 5,157,144, columns 17-18. Methyl 2-(bromomethyl)phenylglyoxylate O-methyloxime is prepared from methyl 2-methylphenyl-acetate by treatment with an alkyl nitrite under basic conditions to provide after methylation, methyl 2- methyl-phenyl-glyoxalate O-methyl oxime which can also be prepared from methyl 2-methyl-phenylglyoxalate by treatment with 2-hydroxylamine hydrochloride and methylation or by treatment with methoxylamine hydrochloride. Scheme B As shown in scheme B compounds of formula IX (X is N) and of Tables 3, 6, 9, and 12 can be prepared by the aminolysis of oximinoacetate (VII). The aminolysis of oximinoacetate to oximinoacetamides has been described in US Patent Numbers 5,185,342, cols. 22, 48 and 57, 5,221,691, cols. 26-27 and 5,407,902 , col. 8. For example, compounds of formula VII and of Table 2 are treated with 40% aqueous methylamine in methanol to provide compounds of formula IX and of Table 3 of formula I where Z is NH. Alternatively, as is shown in scheme B intermediate unsaturated oximes (V) are reacted with N- methyl (E)-2-methoxyimino-2-[2-(bromomethyl)phenyl]acetamide VIII in the presence of a base such as an hydroxide base preferably in a solvent such as acetone or methyl ethyl ketone to provide compounds of formula (IX). N-methyl (E)-2-methoxy-imino-2-[2-(bromomethyl)phenyl]acetamide is described in US Patent Number 5,387,714, col. 13. The oximes of the general formula (V) can be obtained, as shown in Scheme C, by reacting the corresponding cyclopropyl aldehyde or ketone (X) with hydroxylamine hydrochloride from room temperature to reflux, preferably at room temperature, in an appropriate solvent such as methanol or ethanol in the presence of an appropriate alkali such as sodium hydroxide, potassium carbonate or pyridine. A general description of the synthesis of oximes with hydroxylamine is described in March, Advanced Organic Chemistry, 4th Ed, pp. 906-907 and references therein. The oximes of the general formula (III) when obtained as a mixture of syn or anti oxime isomers can be separated into individual isomers and alkylated as described in scheme A and B. When a mixture of oximes of the general formula (III) are used in Schemes A and B the compounds of the formula VI, VII and IX can be separated into their individual isomers by conventional chromatographic techniques. Scheme C (X) (V) The cyclopropyl aldehydes or ketones (X) are prepared by conventional techniques. The unsaturated intermediate XI (Scheme D) is reacted with a sulfur ylide, prepared from a dimethylsulfoxonium salt in the presence of a base, resulting in the substituted acyl cyclopropanes, X, as shown in Scheme D. The chemistry of sulfur ylides is described in Trost and Melvin, Sulfur Ylids , Academic Press, New York, NY 1975 and in Block, Reactions of Organosulfur Compounds, pp. 91-123, Academic Press, New York, NY 1978. Typical reaction conditions for sulfur ylide formation from a dimethylsulfoxonium salt utilizes bases such as hydroxides, metal hydrides and alkoxides in solvents such as dimethoxy ethane, dimethylsulfoxide and water depending on the base employed. The reactions are conducted from 0 to 20°C preferably from 10-15°C and preferably with alkali metal hydroxides in dimethylsulfoxide. Typically dimethylsulfoxonium methylide is prepared from trimethylsulfoxonium iodide in dimethylsulfoxide in the presence of powdered sodium hydroxide at room temperature. The unsaturated aldehydes or ketones (XI) are added dropwise to the ylide and stirred at room temperature. Scheme D XI X The ,β-unsaturated aldehydes or ketones XI can be prepared by conventional condensation techniques. A extensive description of the synthesis of α,β-unsaturated aldehydes or ketones (enones) is described in March, Advanced Organic Chemistry. 4th Ed, pp. 937-955 and references therein. For example Organic Reactions. Volume 16 describes the general aldol condensation of ketones and aldehydes. For intermediates of formula XI of this invention, in general the ketones and aldehydes are R 7 COR 6 (XII) and R 2 COCH 2 R 3 (XIII) where R 2 , R 3 , R 6 , and R 7 are defined previously. When R 6 is hydrogen, the aldehydes R 7 CHO (XIV), are for example benzaldehydes (arylCHO) or heterocyclic aldehydes substituted with from 2 to 5 substituents wherein the positions on the aryl and heterocyclic ring adjacent to the bond to the cyclopropyl ring, in Formula I, are both substituted. These substituted benzaldehyes or heterocyclic aldehydes are commerically available or prepared by conventional techniques. The aldehydes R 7 CHO (XIV) are reacted with the ketones R 2 COCH 2 R 3 , XIII, (as shown in Scheme E) to provide the intermediates enones XV. Typically the ketone, R 2 COCH 2 R 3 , is dissolved in a hydroxylic solvent, such as methanol or ethanol, to which is added drop wise the aldehyde R 7 CHO followed by the base or alternatively a solution of the aldehyde in an aqueous basic solution is added. The typical bases used can be alkali metal hydroxides, such as barium, potassium or sodium hydroxide and the dropwise addition is conducted from 0°C to 35°C preferably at ambient temperature. When the enone is derived from acetone (R 2 is methyl and R 3 is hydrogen) the solvent can be acetone to which is added R 7 COR 6 followed by the aqueous hydroxide solution. Preferably the aldehyde is dissolved in a solvent mixture of acetone:water (1:5) to which is added the base while stirring at room temperature. Scheme E When R 6 is not hydrogen, R 7 COR 6 (XII) are the ketones arylCOR 6 or heterocyclic ketones, substituted with from 2 to 5 substituents wherein the positions on the aryl and heterocyclic rings adjacent to the bond to the cyclopropyl ring, in Formula I, are both substituted or aryl or heterocyclic ring is unsubstituted or substituted from 1 to 4 substituents wherein at least one of the positions on the aryl or heterocyclic rings adjacent to the bond to the cyclopropyl ring, in Formula I, is a hydrogen. For the compounds of formula I where R 6 is not hydrogen the intermediate unsaturated aldehydes and ketones XI are prepared, as shown in Scheme F, according to the procedures described in US Patent Number 3,950,427, col. 17 line 20, to provide after purification the E diastereiosmer (R 7 is trans to R 2 CO in XI). In a typical preparation a ketone such as R 7 COR 6 is reacted with an ethyl trans 3-ethoxycrotonate in dimethylformamide in the presence of potassium t-butoxide followed by acidic hydrolysis and decarboxylation to give XI. The crotonates, XVI , can be prepared from substituted ethyl acetoketones by conventional techniques Scheme F XII XI Alternatively the α,β-unsaturated cyclopropyl ketones X can be prepared from cyclopropyl nitriles XIV which are prepared via cyclop ropanation of the acrylonitriles XVIII as is described in Scheme G. The acrylonitriles XVIII starting materials, shown in Scheme G can be prepared by conventional synthetic methods as described in March, Advanced Organic Chemistry, 4th Ed, pp. 937-955 and references therein . For example the nitrile derivative R 3 CH 2 CN is condensed with the ketone or aldehyde R 7 COR 6 in the presence of a base to provide the acrylonitriles XIII. Typically the a nitrile is dissolved in a solvent such as ethanol and water to which is added the aldehyde or ketone followed by a base. Typical bases used can be alkali metal hydroxides, such as barium, potassium or sodium hydroxide and the mixture is stirred typically at ambient temperature. The acrylonitrile XVIII is treated as is described in Scheme D with a sulfur ylide to provide the cyclopropyl nitriles XVII. The cyclopropyl nitrile XVII is transformed to the cyclopropyl ketone by organometallic addition to the nitrile followed by hydrolysis. For example the standard Grignard reagents R 2 MgX or organolithium reagents, R 2 Li, add to the nitrile functionality to provide the ketone X. The addition reaction to nitriles is described in March, Advanced Organic Chemistry, 4th Ed, pp.935-936 and references cited therein. The cyclopropyl nitrile XVII can be transformed to the cyclopropyl aldehyde X' (where R 2 is H) by standard reductive methods such as with diisobutylaluminum hydride (DiBAL). The formation of aldehydes from the reduction of nitriles is described in March, Advanced Organic Chemistry, 4th Ed, pp.919-920 and references cited therein. Scheme G XVIII XVII X A direct synthesis of compounds of the formula VII or IX is shown in Scheme H. Compounds of the Formula VII or IX can be prepared directly from the functionalized cyclopropyl ketones or aldehydes, X, by condensation with the aminoxy intermediate XIX. The preparation of aminoxy intermediate XIX is described in US Patent Number 5,194,662. The aminoxy intermediate XIX is prepared in a two step sequence by the alkylation of IV (where X is N) with N- hydroxyphthalimide which is treated with hydrazine to provide XIX. The aminoxy intermediate XIX is condensed with ketones or aldehydes X to provide VII which are treated as shown in scheme B to provide IX. Scheme H XIX X VII The compounds of this invention can be made according to the following procedures: Example 1 Preparation of E and Z imine isomers: (E.E) and (Z.E) Methyl 2-T2- ((trans-l-(2-(2'.6 , -dichlorophenyl)cyclopropyl)ethylidene)- aminooxymethyl)phenyn-2-methoxyiminoacetate Compound 8.16, 8.16A and 8.16B of Table 8 Preparation of 4-,2.6-dichlorophenyl)-3-buten-2-one To a 1000 ml round bottom flask equipped with mechanical stirrer, and nitrogen inlet were charged 26.5 g (0.15 moles) of 2,6-dichlorobenzaldehyde, 125 mis of acetone, 600 mis of water, and 9.3 g (0.23 moles) of sodium hydroxide. The mixture was stirred for 12 hours at room temperature. Analysis of an aliquot by GC indicated complete reaction. The resulting solid was collected by vacuum filtration, and washed with 100 mis of water, 100 mis of hexane, and dried in vacuuo at 40°C for 3 hours. 31.4 g of the title compound ,4-(2,6-dichlorophenyι)-3- buten-2-one, was isolated as a pale yellow solid in 98% isolated yield. NMR 300 MHz Η CDCI3 2.43 (s, 3H); 6.80 (d, 1H); 7.18-7.38 ( , 1H); 7.4 (d, 2H); 7.6 (d, 1H). Preparation of trans-l-(2,6 dichlorophenyT)-2-acetyl-cvclopropane To a 1000 ml round bottom flask equipped with magnetic stirrer, nitrogen inlet and addition funnel were charged 33.2 g (0.151 moles) of trimethyl sulfoxonium iodide, 6.1 g (0.151 moles) of powdered sodium hydroxide, and 300 mis DMSO. The mixture was stirred at room temperature for 1 hour, followed by the rapid addition of the 4-(2,6-dichlorophenyl)-3-buten-2-one (32.3 g, 0.151 moles) in one portion. The reaction was then stirred for 10 minutes at ambient temperature, then poured into 200 mis of ice water and extracted with 3 x 100 ml of ethyl ether. The ether extract was washed with 2 x 100 mis of water, lOOmls of brine, dried over anhydrous MgSO4, filtered through 2" of silica gel, and concentrated in vacuuo on a rotary evaporator to afford 31.7 g of a thick pale yellow oil which was chromatographed on silica gel with 90% hexane, 10% ethyl acetate. The pure fractions were combined and concentrated in vacuuo on a rotary evaporator to afford 27.9 g of trans-l-(2,6 dichlorophenyl)-2-acetyl- cyclopropane as a free flowing pale yellow liquid.in 81% yield. NMR 300 MHz Η CDC1 3 1.4-1.48 (m, 1H); 1.78-1.86 (m, 1H); 2.21-2.30 (m, 1H); 2.34-2.4 ( , 1H); 2.41 (s, 3H), 7.2 (m, 1H), 7.3 (d, 2H). Preparation of E and Z imine isomers: (E.E) and (Z.E) Methyl 2-T2-((trans-l-(2- (2',6'-dichlorophenyl)cvclopropyl)ethylidene)aminooxymethyl)phenyll-2- methoxyiminoacetate To a 100 ml round bottom flask equipped with magnetic stirrer were charged 1.0 g (0.0044 moles) of the trans-l-(2,6 dichlorophenyl)-2-acetyl- cyclopropane, 1.1 g (0.0044 moles) of the methyl (E)-2-(aminooxymethyl)phenyl glyoxylate O-methyloxime, and 50 mis of anhydrous methanol. The reaction was stirred overnight at room temperature. Analysis of an aliquot by GC indicated no starting material and two new products. The reaction was then poured into 100 mis of water and extracted with 3 x 50 ml of ethyl ether. The ether extract was washed with 100 mis of water, 100 mis of 0.1N HC1, and lOOmls of brine, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuuo on a rotary evaporator to afford 2.0g of a thick yellow oil which was chromatographed on silica with 20 % ethyl acetate/ 80% hexane. The pure fractions were combined and concentrated in vacuuo on a rotary evaporator to afford 1.4 g of the methyl 2-[2-((trans-l-(2-(2',6'-dichlorophenyl)cyclopropyl)- ethylidene)aminooxymethyl)phenyl]-2-methoxyiminoacetate as a pale yellow oil as a 90/10 A:B (E,E:E,Z) isomer ratio in 72% isolated yield. NMR 300 MHz Η CDC1 3 1.3 (m, 1H); 1.7 (m, 1H); 1.85 (s, 3H); 1.95 (m, 1H); 2.2 (m, 1H); 3.85 (s, 3H), 4.1 (s, 3H); 5.0 (s, 2H); 7.1 (m, 1H), 7.2 (m, 1H); 7.3 (d, 2H); 7.4-7.6 (m, 3H). An additional 10. Og of the crude product as an orange oil (85% chemically pure and 2:1 A:B isomers) was chromatographed on silica with 20 % ethyl acetate/ 80% hexane. 5.02 grams of isomer A as a pale yellow oil was collected (E:E)- methyl 2-[2-((trans-l-(2-(2',6'-dichlorophenyl)cyclopropyl)ethylidene)- aminooxymethyl)phenyl]-2-methoxyiminoacetate. Compound 6A, Isomer A, E imine, NMR (300MHz., Η CDCI3): 1.19-1.30 (1H, m), 1.50-1.58 (1H, m), 1.75- 1.85 (1H, m) 1.84 (3H, s), 2.06-2.14 (1H, m), 3.85 (3H, s), 4.05 (3H, s), 4.98 (2H, s), 7.03-7.49 (7H, m). 0.825 grams of isomer B as a pale yellow oil was collected (E:Z)-methyl 2-[2-((trans-l-(2-(2',6'-dichlorophenyl)cyclopropyl)ethylidene)- aminooxymethyl)phenyl]-2-methoxyiminoacetate. Compound 8.16B, Isomer B, Z imine, NMR (300MHz., Η CDCI3): 1.21-1.28 (1H, m), 1.40-1.52 (1H, m), 1.70 (3H, s), 2.18-2.23 (1H, m) 2.61-2.70 (1H, m), 3.80 (3H, s), 4.00 (3H, s), 4.97 (2H, s), 7.05-7.52 (7H, m). Preparation of methyl (E)-2-(aminooxymethyl)phenyl glyoxylate O-methyloxime Methyl (E)-2-(O-phthalimidoxymethyl)phenyl glyoxylate O-methyloxime To a dry 500 ml round bottom flask equipped with magnetic stirrer, and nitrogen inlet were charged 5.1 g (0.0315 moles) of N-hydroxyphthalimide, 1.3 g (0.0315 moles) of sodium hydroxide, and 300 ml of anhydrous dime thy lformamide. The dark red solution was stirred at ambient temperature for 20 min., followed by the addition of the methyl 2-(bromomethyl)- phenylglyoxylate-O-methyloxime (15 g, 60% pure, 0.0315 moles) in one portion. The reaction was stirred at ambient temperature over the weekend, then poured into 800 mis of water and stirred for 1 hour to afford a white solid which was collected by vacuum filtration and washed with water, hexane, and dried under vacuum at 40°C overnight. Isolated 11.5g of a white solid (98% isolated yield) which was consistent with the desired product, methyl (E)-2-(O- phthalimidoxymethyl)phenyl glyoxylate O-methyloxime, upon analysis by 300 MHz Η NMR (300 MHz, Η, CDCI3, TMS=0 ppm) 3.8 (s, 3H), 3.95 (s, 3H), 5.0 (s, 2H), 7.1 (d, 1H), 7.5 (m, 2H), 7.7-7.9 ( , 5H). Preparation of methyl (E)-2-(aminooxymethyl)phenyl glyoxylate O-methyloxime. To a 250ml round-bottom flask equipped with magnetic stirrer were charged 11.4 g (0.031 moles)of methyl (E)-2-(O-phthalimidoxymethyl)phenyl glyoxylate O-methyloxime 100 mis of anhydrous methanol, and 1.9 g (0.034 moles)of hydrazine monohydrate. The flask was stoppered, and the reaction was stirred at ambient temperature for 2 hours. The resulting solid was removed by filtration and the filtrate was concentrated on the rotary evaporator. The residue was dissolved in 100 mis of ether, filtered, and stripped to afford 7.4 g of a thick yellow oil (100% isolated yield), which was consistent with the desired product methyl (E)-2-(aminooxymethyl)phenyl glyoxylate O-methyloxime upon analysis by 300 MHz Η NMR. Stored at -20°C until needed for future synthesis. NMR (300 MHz, 1H, CDC1 3 , TMS=0 ppm) 3.87 (s, 3H), 4.03 (s, 3H), 4.6 (s, 2H), 4.9-5.4 (bs, 2H), 7.2 (m, 1H), 7.4-7.5 (m, 3H). Example 2 Preparation of E and Z imine isomers: (E,E) and (Z,E)-N-Methyl 2-f2- ((trans-l-(2-(2 , ,β , -dichlorophenyl)cyclopropyl)ethylidene)- aminooxymethyl)phenyl1-2-methoxyiminoacetamide Compounds 9.16, 9.16A, 9.16B of Table 9. To a 100 ml flask equipped with magnetic stirrer and were charged 0.7 g (0.00115 moles) of (E,E:Z,E)-methyl 2-[2-((trans-l-(2-(2',6'- dichlorophenyl)cyclopropyl) ethylidene)aminooxymethyl)phenyι]-2- methoxyiminoacetate, 50 mis of methanol, and 2 mis (0.026 moles) of 40% aqueous methyl amine solution. The mixture stirred at ambient temperature overnight, then poured into 200 is of water and extracted with 3 x 100 ml of ethyl ether. The ether extract was washed with 2 x 100 mis of water, 100 mis of 0.1 N HC1 , and lOOmls of brine, dried over anhydrous MgSO 4 , filtered, and concentrated in vacuuo on a rotary evaporator to afford 0.6g of N-Methyl 2-[2- ((trans-l-(2-(2',6'-dichlorophenyl)cyclopropyl)ethylidene)aminooxymethyl)- phenyl]-2-methoxyiminoacetamide as a thick viscous pale yellow oil. 90/10 A:B (E,E:Z,E) isomers ratio in 88% isolated yield. NMR 300 MHz, Η CDC1 3 1.2 (m, 1H); 1.6 (m, 1H); 1.8 (s, 3H); 1.9 ( , 1H); 2.2 ( , 1H); 2.9 (d, 3H); 3.95 (s, 3H), 5.0 (s, 2H); 6.7 (bs, 1H); 7.1 (m, 1H), 7.2 (m, 1H); 7.3 (d, 2H); 7.4-7.6 (m, 3H). Additionally each of 8.16A and 8.16B oxime esters was separately treated as above with methylamine. Aminolysis of 5.01 grams of 8.16A (E,E isome ) gave 5.02 grams (100% yield) of (E,E)-N-methyl 2-[2-((trans-l-(2-(2',6'- dichlorophenyl)cyclopropyl)ethylidene)aminooxymethyl)phenyl]-2- methoxyiminoacetamide as an oil. The oil was treated with ether, concentrated and cooled in dry ice followed by the addition of hexane to complete the crystallization. The resulting crystals were flitered to give a solid mpt. 94-97°C. Compound 9.16A, Isomer A, E,E isomer, NMR (300MHz, *H CDCI3): 1.20-1.30 (1H, m), 1.51-1.58 (1H, m), 1.80-1.89 (1H, ), 1.82 (3H, s), 2.2 (lH,m), 2.89 (3H, d), 3.96 (3H, s), 4.98 (2H, s), 6.70 (1H, br), 7.05-7.48 (7H, m). Aminolysis of 0.825grams of 8.16B (Z,E isomer ) gave 0.825 grams (100% yield) of (Z,E)-N-methyl 2-[2-((trans-l-(2-(2',6'- dichlorophenyl)cyclopropyl)ethylidene)aminooxymethyι)phenyl]-2- methoxyiminoacetamide as solid, mpt. 140-146°C. Compound 9.16B, Isomer B, Z,E isomer, NMR (300MHz, Η CDCI3): ): 1.22-1.30 (1H, m), 1.40-1.51 (1H, m), 1.70 (3H, s), 2.15-2.23 (1H, m), 2.60-2.69 (lH,m), 2.85 (3H, d), 3.90 (3H, s), 4.97 (2H, s), 6.70 (1H, br), 7.09-7.51 (7H, m). Example 3 Preparation of E and Z imine isomers: (E.E) and (Z.E) Methyl 242- difluorophenyl)cyclopropyl)ethylidene)aminooxymethyl)phenyll-2- methoxyiminoacetate Compound 8.22 of Table 8 Preparation of 4-(2.6-difluorophenyl -3-buten-2-one To a 100ml reaction bottle equipped with magnetic stir bar were charged 5.0g (35.2mmole) 2,6-difluorobenzaldehyde in 20 ml acetone, added 50% NaOH (42 mmole) in 60ml water (exothermic) and stirred room temperature. The reaction was monitored by GLC and after 2 hours worked up. The reaction mixture was extracted with 50ml CHCI3, washed with 50ml H 2 O, dried over anhydrous MgSθ4, filtered, and removed solvent in vacuuo on a rotary evaporator to afford 5.7g of 4-(2,6-difluoro-phenyl)-3-buten-2-one as a yellow oil (81% purity by GC) in 89.5% isolated yield. NMR (300 MHz Η CDC1 3 ): 2.4 (s, 3H); 6.9 (m, 3H); 7.3 (m, 1H); 7.6 (d, 1H). Preparation of trans-l-(2,6 difluorophenyl)-2-acetyl-cyclopropane To a 500 ml round bottom flask equipped with magnetic stirrer, nitrogen inlet and addition funnel was charged 2.47 g (11.2 m oles) of trimethyl sulfoxonium iodide, 0.448g (11.2mmole) of powdered sodium hydroxide, and 50 mis DMSO. The mixture was stirred at room temperature for 0.5 hour, followed by the rapid addition of 2.04g (11.2mmole) 2,6-difluoro-phenyl-3-buten-2-one in 25ml DMSO in one portion. The reaction was stirred for 15 minutes at ambient temperature, poured into 200 mis of ice water, and then extracted with 150 ml of ethyl ether. The ether extract was washed with 4 x 100 mis of water, dried over anhydrous MgSO 4 , filtered, and concentrated in vacuuo on a rotary evaporator to afford 1.3 g crude product as a yellow oil. This was combined with 1.6g from a similar reaction and the total crude of 2.9g was chromatographed on silica with CH 2 C1 2 . Fractions (#5-9) were combined and concentrated in vacuuo on a rotary evaporator to afford 1.5g (92% purity by GC) of trans-l-(2,6 difluorophenyl)-2- acetylcyclopropane as a free flowing pale yellow liquid, in 28.8% yield. NMR (300 MHz Η CDC13): 1.6 ( , 2H); 2.3 (s, 3H); 2.4 (m, 2H); 6.8 (m, 2H), 7.1 (m, 1H). Preparation of E and Z imine isomers: (E.E and (Z.E) Methyl 2-T2-((trans-l-(2- (2 , .6'-difluorophenyl)cyclopropyl)ethylidene)aminooxymethyl)phenyl1-2- methoxyimino acetate To a 25ml reaction vial equipped with magnetic stirrer were charged 1.0 g (0.0051 moles) of the trans-l-(2,6 difluorophenyl)-2-acetyl-cyclopropane and 1.33 g (0.0056 moles) of the methyl (E)-2-(aminooxymethyl)phenyl glyoxylate O- methyloxime in 5 mis of anhydrous methanol and 5 drops glacial acetic acid. The reaction was stirred 4 hours at room temperature with formation of precipitate. The sample was refrigerated overnight and then worked up. The white precipitate was filtered in vacuuo, washed with 2 x 10ml hexane, and dried in the vacuum oven at ambient to afford l.lg of the methyl 2-[2-((trans-l- (2-(2',6'-difluorophenyl)cyclopropyl)ethylidene)aminooxy- methyl)phenyl]-2-methoxyiminoacetate as a white solid, mpt. 81-88°C, as a 79:21 A:B (E:E,Z:E) isomer ratio in 51.9% isolated yield. NMR (300 MHz Η CDC13): 1.4 (t, 2H); 1.65-1.8 (d, 3H); 2.1 (m, 2H); 3.8 (d, 3H); 4.0 (d, 3H); 5.0 (s, 2H); 6.8 (m, 2H), 7-7.2 (m, 2H); 7.3-7.5 (m, 3H). Example 4 Preparation of E and Z imine isomers: (E.E and (Z.EVN-Methyl 2-f2- difluorophenyl)cyclopropyl)ethylidene)aminooxymethyl)phenvIl-2- methoxyiminoacetamide Compounds 9.22A, 9.22B of Table 9. To a 25ml reaction test tube under nitrogen atmosphere were charged 0.95g of (E,E:Z,E)-methyl 2-[2-((trans-l-(2-(2',6'- difluorophenyl)cyclopropyl)ethylidene)- aminooxymethyι)phenyl]-2- methoxyiminoacetate(2.3mmole) in 7ml MeOH and 1.8g 40% aqueous methyl amine (23mmole) which was heated at 55-60C. The reaction was monitored by TLC and worked up after 1.5 hours. Removed the methanol in vacuuo on the rotary evaporator at 30°C. To the residue was added 125ml ethyl acetate and 50ml water, partitioned, further washed the organic phase with 2 x 50ml water, dried over anhydrous MgSO4, filtered, and concentrated in vacuuo on the rotary evaporator at 40°C to give lg of (E,E:Z,E)-N-methyl 2- [2- ((trans- 1- (2- (2', 6'- difluorophenyl)cyclopropyl)ethylidene)aminooxymethyl)phenyl]-2-methoxyimino- acetamide as a 76:24 A:B (E,E:Z,E) isomer ratio. This mixture was chromatographed on silica with 1:2 ethyl acetate: hexane to afford both (E,E) and (Z,E) isomers of the N-methyl 2-[2-((trans-l-(2-(2',6'difluorophenyl)- cyclopropyl)ethylidene)aminooxy-methyl)phenyl]-2-methoxyiminoacetamide. 700mg of isomer-A (E,E) was isolated as a clear oil and 150mg isomer B (Z,E) was isolated also as a pale yellow oil. The chromatrographed combined isolated yield was 89.5%. Compound 9.7A, Isomer A, E,E isomer: NMR (300 MHz Η CDC13) 1.4 (t, 2H); 1.8 (s, 3H); 2.1 (m, 2H); 2.9 (d, 3H); 3.9 (s, 3H); 4.9 (s, 2H); 6.1 (bs, 1H); 6.8 (t, 2H); 7-7.2 (m, 2H); 7.3-7.5 (m, 3H). Compound 9.7B, Isomer B, Z,E isomer NMR (300 MHz Η CDC13) 1.3 (m, 1H); 1.6 (m, 4H); 2.1 (m, 1H); 2.8 (m, 4H); 3.9 (s, 3H); 4.9 (s, 2H); 6.1 (bs, IH); 6.8 (t, 2H); 7-7.2 (m, 2H); 7.3-7.5 (m, 3H). Example 5 Preparation of Methyl 2-[2-((l-(2-(4'-chlorophenyD-2- methylcyclopropyl)- ethylidene)aminooxymethyl)phenyl1-2-methoxyiminoacetate Compound 2.14A of Table 2. Preparation of E and Z enone isomers of 4-(4-chlorophenvD-3-penten-2-one To a 500 ml round bottom flask equipped with magnetic stirrer, nitrogen inlet and addition funnel were charged lOg (0.065 moles) of 4'- chloroacetophenone, 10.2g (0.065 moles) of ethyl-trans-3-ethoxycrotonate, and 150 mis of dry dimethylformamide. To this solution was then added 7.3 g (0.065 moles) of potassium t-butoxide in one portion. The reaction was stirred at ambient temperature under nitrogen for a total of three days. The reaction mixture was then poured into 200 mis of water and the aqueous was extracted with 3 x 50 mis of ethyl ether to remove any unreacted starting material. The aqueous fraction was acidified to pH 2 with 1 N aqueous HC1, and extracted with 3 x 100 mis of ethyl ether. The ether extract was washed with 2 x 100 mis of water and 100 mis of saturated sodium chloride solution, dried over anhydrous magnesium sulfate, filtered, and concentrated on a rotary evaporator to afford 12.4 g of a tan solid. This solid was then stirred in 50 mis of cone. HC1 for 2 hours at ambient temperature, then poured into 100 g of crushed ice, and extracted with 3 x 100 ml of ethyl ether. The ether extract was washed with 2 x 100 mis of water, lOOmls of brine, dried over anhydrous magnesium sulfate, filtered, and concentrated on a rotary evaporator to afford 7.6 g of a yellow liquid, 4-(4-chlorophenyl)-3-penten-2-one, which appeared to be a mixture of the E and Z enones, with some minor chemical impurities, in 59.3 % crude yield. The product was used in the next step without further purification. 300 MHz Ή NMR (tms=0 ppm) 2.3 (s, 3H); 2.5 (s, 3H); 6.5 (s, IH); 7.3-7.5 (m, 4H). Preparation of trans and cis-l-(4-chlorophenyl)-l-methyl-2-acetylcvclopropane To a 250 ml round bottom flask equipped with magnetic stirrer, nitrogen inlet and addition funnel were charged the trimethyl sulfoxonium iodide (8.5 g, 0.0386 moles), powdered sodium hydroxide (1.6 g, 0.0386 moles) and 100 mis of dry DMSO. The mixture was stirred at room temperature for 1 hour, followed by the rapid addition of the (E >Z)-4-(4-chlorophenyl)-3-penten-2-one (7.5 g, 0.0386 moles)) in 10 mis DMSO. The reaction was stirred for 3 days at ambient temperature, then poured into 200 mis of ice water and extracted with 3 x 100 ml of ethyl ether. The ether extract was washed with 2 x 100 mis of water, lOOmls of brine, dried over anhydrous MgSO4, filtered through 2" of silica gel, and concentrated on a rotary evaporator to afford 3.2 g of a thick pale yellow oil which was chromatographed on silica gel with 10 % ethyl acetate, 90% hexane. The pure fractions were combined and concentrated on the rotary evaporator to afford 1.4 g (17.2% isolated yield) of a pale yellow liquid which was consistent with trans and cis-l-(4-chlorophenyl)-l-methyl-2-acetylcyclopropane upon analysis by 300Mz IH NMR. 300 MHz Η NMR (tms=0 ppm) 1.2 (m, IH); 1.4 (s, 3H); 1.6 (m, IH); 2.2 (m, IH); 2.35 (s, 3H); 7.1-7.4 (m, 4H). Preparation of Methyl 2-[2-((l-(2-(4'-chlorophenyl)-2-methylcyclopropyl)- ethylidene)aminooxymethyl)phenyll-2-methoxyiminoacetate To a 20 ml glass vial equipped with magnetic stirrer were charged the 1.0 g (0.0048 moles ) of the trans and cis-l-(4-chlorophenyl)-l-methyl-2- acetylcyclopropane, 1.2 g (0.0048 moles) of the methyl (E)-2- (aminooxymethyl)phenyl glyoxylate O-methyloxime, and 10 mis of dry methanol. The vial was capped, and stirred overnight at ambient temperature. The reaction mixture was then poured into 100 mis of water and extracted with 3 x 100 ml of ethyl ether. The ether extract was washed with 2 x 100 mis of water, lOOmls of 1 N HC1, and lOOmls of saturated sodium chloride solution, dried over anhydrous MgSO4, filtered, and concentrated on a rotary evaporator to afford 1.6 g of a thick orange oil which was chromatographed on silica gel with 20% ethyl acetate, 80% hexane. The pure fractions after chromatography were combined and concentrated on a rotary evaporator to afford 0.75 g of a clear colorless viscous oil (36.5% isolated yield) which was consistent with isomer A, (E,E)- methyl 2-[2-((l-(2-(4'-chlorophenyl)-2-methylcyclopropyl)ethylidene) aminooxymethyl)phenyl]-2-methoxyiminoacetate upon analysis by 300 MHz Η NMR with a 70:30 ratio of cyclopropane isomers. 300 MHz i H NMR (tms=0 ppm) 1.15 (s, 3H) 1.2 (m, IH); 1.4 (m, IH); 1.6 (m, IH); 2.0(s, 3H); 3.85 (s, 3H); 4.0 (s, 3H); 5.0 (s, 2H); 7.1-7.3 (m, 5H); 7.35-7.6 (m, 3H) Example 6 Preparation of (E.E N-Methyl 2-r2-((l-(2-(4'-chlorophenyl)-2-methyl cyclopropyl)-ethylidene)aminooxymethyl)phenyπ-2- methoxyiminoacetamide Compound 3.14A of Table 3. To a 100 ml round bottom flask equipped with magnetic stirrer were charged 0.7 g (0.00163 moles) of the (E,E)-methyl 2-[2-((l-(2-(4'-dichloroρhenyl)- 2-methylcyclopropyl)ethylidene)aminooxymethyl)phenyl]-2- methoxyiminoacetate, 25mls of anhydrous methanol, and 1 ml (0.0129 moles) of 40% methyl amine in water. The flask was stoppered, and stirred overnight at ambient temperature. The reaction mixture was then poured into 100 mis of water and extracted with 3 x 50 ml of ethyl ether. The ether extract was washed with 2 x 50 mis of water, 50 mis of 1 N HC1, 50mls of saturated sodium chloride solution, dried over anhydrous MgSO4, filtered, and concentrated on a rotary evaporator to afford 0.7 g of a yellow viscous oil which was chromatographed on silica gel with 20% ethyl acetate, 80% hexane. The pure fractions were combined and concentrated on a rotary evaporator to afford 0.55 g of a clear colorless viscous oil (79% isolated yield) which was consistent with isomer A (E,E)-N- ethyl 2-[2-((l-(2-(4'-chlorophenyl)-2-methylcyclopropyl)ethylidene) aminooxymethyl)phenyl]-2-methoxyiminoacetamide upon analysis by 300Mz 1 H NMR and as 70:30 mixture of cyclopropane isomers 300 MHz Η NMR (tms=0 ppm) 1.15 (s, 3H) 1.2 (m, IH); 1.4 (m, IH); 1.65 (m, IH); 2.0(s, 3H); 2.9 (d, 3H); 4.0 (s, 3H); 5.0 (s, 2H); 6.8 (bs, IH); 7.1-7.3 (m, 5H); 7.35-7.6 (m, 3H). Example 7 Preparation of Methyl 2 2-((trans-l-(2-phenyl-2-methylcyclopropyl) ethylidene)aminooxymethyl)phenyll-2-methoxyiminoacetate Compound 2.11 of Table 2. To a 25ml reaction vial equipped with magnetic stirrer were charged 217mg (1.25 mmole) of the trans-l-phenyl-l-methyl-2-acetylcyclopropane and 298 mg (1.25 mmole) of the methyl (E)-2-(aminooxymethyl)phenyl glyoxylate O- methyloxime in 5 ml of anhydrous methanol and 1 drop glacial acetic acid. The reaction was monitored by GC and after 3 hours 90mg more of the methyl 2- (bromomethyI)phenyl glyoxylate O-methyloxime was added and 5 drops of glacial acetic acid. After stirring 20 hours no more starting material ketone remained and the reaction was worked up. The methanol was removed in vacuuo on the rotary evaporator. To the residue was added 100ml ethyl acetate and 50ml water, partitioned, further washed the organic phase with 3 x 50ml water, dried over anhydrous MgSθ4, filtered and concentrated in vacuuo on the rotary evaporator to give 0.6g of yellow oil with solid which was chromatographed on silica with 30:70 ethyl acetate:hexane. The pure fractions were combined to afford 260mg of a clear oil(isolated yield 52.8%) whose NMR was consistent with methyl 2-[2-((trans-l-(2-phenyl-2-methyl- cyclopropyl)ethylidene)aminooxymethyl)phenyl] -2-methoxyiminoacetate as a mixture of isomers, A>B. NMR (300 MHz Η CDC13): 1.1- 1.4 (m, 5H); 1.75 (m, IH); 2.0 (s, 3H); 3.85 (s, 3H); 4.05 (s, 3H); 5.0 (s, 2H); 7.1-7.5 (m, 9H). Example 8 Preparation of (E.E and Z.E)-N-Methyl 2-r2-((trans-l-(2-phenyl-2- methyl-cyclopropyl)ethylidene)aminooxymethyl)phenyll-2- methoxyiminoacetamide Compound 3.11 of Table 3. To a 25ml reaction test tube under nitrogen atmosphere were charged 160 mg of the methyl 2-[2-((trans-l-(2-phenyl-2-methyl- cyclopropyl)ethylidene)aminooxy-methyl)phenyl] -2-methoxyiminoacetate ( 0.41 mmole) in 3ml MeOH and 315 mg 40% aqueous methyl amine (4.1 mmole) which was heated at 55-60C. Monitored by TLC and worked up after 1.5 hours. Removed the methanol in vacuuo on the rotary evaporator at 30C. To the residue was added 125ml ethyl acetate and 50ml water, partitioned, further washed the organic phase with 2 x 50ml water, dried over anhydrous MgSO4, filtered and concentrated in vacuuo on the rotary evaporator at 40C to afford 130 mg (isolated yield 80.7%) of (E,E and Z,E)-N-methyl 2-[2-((trans-l-(2-phenyl-2- methyl-cyclopropyl)ethylidene)aminooxymethyl)phenyl]-2- methoxyiminoacetamide as a clear oil in a 4:1 ratio of isomers A to B (E,E:Z,E). NMR (300 MHz Η CDC13): 1.1- 1.4 (m, 5H); 1.75 (m, IH); 1.95 (s, 3H); 2.9 (d, 3H); 3.95 (s, 3H); 5.0 (s, 2H); 6.1 (bs, IH); 7.1-7.5 (m, 9H). Proton NMR data (300MHz) are provided in Table 13 for typical examples of Tables 1 to 12 and are illustrative of the present invention* Table 13 (s, 2H); 6.1 (bs, IH); 7.1-7.5 (m, 9H). 3.12A l.l(m, IH); 1.18(s, 3H); 1.4(m, IH); 1.7( , IH); 2.1(s, 3H); 2.91(d, 3H); 3.96(s, 3H); 5.0(s, 2H); 6.75(b, IH); 7.1-7.5(m, 8H) 3.14A 1.15 (s, 3H) 1.2 (m, IH); 1.4 (m, IH); 1.65 (m, IH); 2.0(s, 3H); 2.9 (d, 3H); 4.0 (s, 3H); 5.0 (s, 2H); 6.8 (bs, IH); 7.1-7.3 (m, 5H); 7.35-7.6 (m, 3H). 3.17 l.l(m, IH); 1.2(s, 3H); 1.3(m, IH); 1.7(m, IH); 2.0(s, 3H); 2.9(d, 3H); 4.0(s, 3H); 5.0(s, 2H); 6.8(bs, IH); 7.1-7.5(m, 8H). 3.18A l.l(m, IH); 1.15(s, 3H); 1.35(m, IH); 1.7( , IH); 2.05(s, 3H); 2.91(d, 3H); 3.96(s, 3H); 4.99(s, 2H); 6.75(b, IH); 6.9-7.5(m, 8H). 3.20 l.l(m, IH); 1.2(s, 3H); 1.3(m, IH); 1.7(m, IH); 2.0(s, 3H); 2.95(d, 3H); 4.0(s, 3H); 5.0(s, 2H); 6.8(bs, IH); 7.0(t, 2H); 7.1-7.5(m, 6H). 3.20B 0.95(m, IH); 1.2(s, 3H); 1.9(s, 3H); 2.0-2.2(m, 2H); 2.85(d, 3H); 3.9(s, 3H); 5.0(s, 2H); 6.8(bs, IH); 6.9(t, 2H); 7.1-7.5(m, 6H) 3.34A 1.0(m, IH); 1.15(s, 3H); 1.4( , IH); 1.7(m, IH); 2.07(s, 3H); 2.91(d, 3H); 3.96(s, 3H); 4.98(s, 2H); 6.75(b, IH); 7.1-7.5(m, 7H) 3.40A 1.05(m, IH); 1.12(s, 3H); 1.3(m, IH); 1.65(m, IH); 2.03(s, 3H); 2.91(d, 3H); 3.96(s, 3H); 4.98(s, 2H); 6.77(m, 3H); 7.1-7.5(m, 5H) 3.166 0.8(m, 3H); l.l(m, IH); 1.2(m, 2H); 1.4-1.7(m, 2H); 2N(s, 3H); 2.85(d, 3H); 4.1(s, 3H); 5.0(s, 2H); 6.8(bs, IH); 7.1-7.4(m, 9H) 3.170A 0.69(t, 3H); 1.05(m, IH); 1.25(m, 2H); 1.5-1.7(m, 2H); 2.02(s, 3H); 2.91(d, 3H); 3.96(s, 3H); 4.98(s, 2H); 6.75(b, IH); 6.9-7.5(m, 8H) 3.178 0.85(m, 3H); l.l-1.4(m, 4H); 1.6(m, 3H); 2.05(s, 3H); 2.95(d, 3H); 4.0(s, 3H); 5.0(s, 2H); 6.8(bs, IH); 7.1-7.4(m, 9H) 3.189 0.8(d, 6H); 1.0(s, 4H); 1.2(s, 4H); 1.3(m, IH); 1.9(m, IH); 2.9(d, 3H); 4.0(s, 3H); 4.85(q, 2H); 6.8(bs IH); 7N-7.4(m, 9H) 3.217A 1.05(m, IH); 1.15(s, 3H); 1.4(m, IH); 1.7( , IH); 2.07(s, 3H); 2.91(d, 3H);3.96(s, 3H); 4.98(s, 2H); 6.75(b, IH); 6.9-7.6(m, 7H) 8.16 1.3 (m, IH); 1.1 ( , IH); 1.85 (s, 3H); 1.95 (m, IH); 2.2 (m, IH); 3.85 (s, 3H), 4.1 (s, 3H); 5.0 (s, 2H); 7.1 (m, IH), 7.2 (m, IH); 7.3 (d, 2H); 7.4- 7.6 (m, 3H). 8.16A 1.19-1.30 (IH, m), 1.50-1.58 (IH, m), 1.75-1.85 (IH, m) 1.84 (3H, s), 2.06-2.14 (IH, m), 3.85 (3H, s), 4.05 (3H, s), 4.98 (2H, s), 7.03-7.49 (7H, m). 8.16B 1.21-1.28 (IH, m), 1.40-1.52 (IH, m), 1.70 (3H, s), 2.18-2.23 (IH, m) 2.61-2.70 (IH, m), 3.80 (3H, s), 4.00 (3H, s), 4.97 (2H, s), 7.05-7.52 (7H, m). 8.22 1.4 (t, 2H); 1.65-1.8 (d, 3H); 2.1 (m, 2H); 3.8 (d, 3H); 4.0 (d, 3H); 5.0 (s, 2H); 6.8 (m, 2H), 7-7.2 (m, 2H); 7.3-7.5 (m, 3H). 8.200 l.l(m, IH); 1.2(s, 3H); 1.4(m, IH); 1.8(m, IH); 2.1(s, 3H); 3.9(s, 3H); 4.1(s, 3H); 5.0(s, 2H); 7.1-7.6(m, 7H) 9.16 1.2 (m, IH); 1.6 (m, IH); 1.8 (s, 3H); 1.9 (m, IH); 2.2 (m, IH); 2.9 (d, 3H); 3.95 (s, 3H), 5.0 (s, 2H); 6.7 (bs, IH); 7.1 (m, IH), 7.2 (m, IH); 7.3 (d, 2H); 7.4-7.6 (m, 3H). 9.16A 1.20-1.30 (IH, m), 1.51-1.58 (IH, m), 1.80-1.89 (IH, m), 1.82 (3H, s), 2.2 (lH,m), 2.89 (3H, d), 3.96 (3H, a), 4.98 (2H, s), 6.70 (IH, br), 7.05- *NMR data for compounds designated by A or B are data for one single stereoisomer for Compounds without designation are a mixture of stereoisomers and the data provided is for the major isomer. Example 9 Numerous compounds of this invention were tested for fungicidal activity in vivo against the diseases described below. The compounds were dissolved in a 1:1 mixture of acetone and methanol and then diluted with a 2:1:1 mixture of water, acetone and methanol (by volume) to achieve the appropriate concentration. The solution was sprayed onto the plants and allowed to dry for two hours. Then the plants were inoculated with fungal spores. Each test utilized control plants which were sprayed with the appropriate solvent and inoculated. For these protective tests, the plants were inoculated one day after treating the plants with the compounds of this invention. The remainder of the technique of each of the tests is given below along with the results for various compounds described herein by the Compound # against the various fungi at a dose of 150 grams per hectare or 38 grams per hectare. The results are percent disease control as compared to the untreated check wherein one hundred was rated as complete disease control and zero as no disease control. The application of the test fungal spores to the test plants was as follows: Wheat Leaf Rust (WLR) Puccinia recondita (f. sp. tritici ) was cultured on 7-day old wheat (cultivar Fielder) over a 12-day period in the greenhouse. Spores were collected from the leaves by settling on aluminum foil. The spores were cleaned by sieving through a 250-micron opening screen and stored dry. The dried spores were used within one month.. A spore suspension was prepared from dry uredia by adding 20 mg (9.5 million spores) per ml of Soltrol oil. The suspension was dispensed into gelatin capsules (0.7 ml capacity) which attach to the oil atomizers. One capsule is used per flat of twenty 2-inch square pots of 7-day old plants, cultivar Fielder. After waiting for at least 15 minutes for the oil to evaporate from the wheat leaves, the plants were placed in a dark mist chamber (18-20°C and 100% relative humidity) for 24 hours. The plants were then placed in the greenhouse and evaluated after 12 days for disease. Wheat Leaf Blotch (SNW) Cultures of Septoria nodorum was maintained on Czapek-Dox V-8 juice agar plates in an incubator at 20sC with alternating periods of 12 hours of light and 12 hours of darkness for 2 weeks. A water suspension of the spores was obtained by shaking the portion of the plate with fungal material in deionized water and filtering through cheesecloth. The spore-containing water suspension was diluted to a spore concentration of 3.0 x 10^ spores per ml. The inoculum was dispersed by a DeVilbiss atomizer over one-week old Fielder wheat plants which had been previously sprayed with the fungicide compound. The inoculated plants were placed in a humidity cabinet at 20°C with alternating 12 hours of light and 12 hours of darkness for 7 days. The inoculated seedlings were then moved to a controlled environment room at 20°C for 2 days of incubation. Disease control values were recorded as percent control. Wheat Powdery Mildew (WPM) Erysiphe graminis (f. sp. tritici) was cultured on wheat seedlings, cultivar Fielder, in a controlled temperature room at 18°C. Mildew spores were shaken from the culture plants onto 7-day old wheat seedlings which had been previously sprayed with the fungicide compound. The inoculated seedlings were kept in a controlled temperature room at 18°C and subirrigated. The percent disease control was rated 7 days after the inoculation. Disease control values were recorded as percent control. Cucumber Powdery Mildew (CPM) Sphaerotheca fulginea was maintained on cucumber plants, cultivar Bush Champion, in the greenhouse. Inoculum was prepared by placing five to ten heavily mildewed leaves in a glass jar with 500ml of water containing 1 drop of Tween 80 (polyoxyethylene monooleate) per 100 ml. After shaking the liquid and leaves, the inoculum was filtered through cheese cloth and misted onto the plants with a squirt bottle mister. The spore count was 100,000 spores/ml. The plants were then placed in the greenhouse for infection and incubation. The plants were scored seven days after inoculation. Disease control values were recorded as percent control. Tomato Late Blight (TLB) Cultures of Phytophthora infestans were maintained on green pea- amended agar for two to three weeks. The spores were washed from the agar with water and dispersed with a DeVilbiss atomizer over the leaves of 3-week old Pixie tomato plants which had been previously treated with compound of the present invention. The inoculated plants were placed in a humidity cabinet at 20°C for 24 hours for infection. The plants were then removed to a controlled environment room at 20°C and 90% humidity. The plants were scored for disease control after five days. Grape Downv Mildew (GDM) Plasmopara viticola was maintained, leaves of grape plants, cultivar Delaware, in a controlled temperature chamber at 20°C in humid air with moderate light intensity for 7 to 8 days. A water suspension of the spores from infested leaves was obtained and the spore concentration was adjusted to about 3 x 10^ per ml of water. Delaware grape plants were inoculated by spraying the underside of leaves with a De Vilbiss atomizer until small drops were observed on the leaves. The inoculated plants were incubated in a mist chamber for 24 hours at 20°C. The plants were then removed to a controlled environmental room at 20°C. Disease control values were recorded as percent control seven days after inoculation. Rice Blast (RB. Cultures of Pyricularia oyrzae were maintained on potato dextrose agar for two to three week. The spores were washed from the agar with water containing 1 drop of Tween 80 per 100ml. After filtering the spore suspension through two layers of cheese cloth, the spore count was adjusted to 5 x i per ml of water. The spore suspension was sprayed onto 12-day old rice plants, cultivar M-l, using a DeVilbiss atomizer. The inoculated plants were placed in a humidity at chamber 20°C for 36 hours to allow for infection.. After the infection period the plants were placed in the greenhouse. After 6 days, the plants were scored for disease control. Disease control values were recorded as percent control. Cucumber Downv Mildew (CDM) The cultures of Pseudoperonospora cubensis were maintained on cucumber plants. Leaves showing excellent sporulation were frozen in glass jars at -40°C. After extracting the spores by shaking the leaves in water, the lower surface of the treated cucumber leaves were sprayed with a spore concentration of 100,000 spores per ml of water. The cucumber plants were placed in a Dew Chamber at 20°C for 24 hr. After this infection period, the plants were placed in a growth chamber at 20°C and 90% humidity for 5 days. After severe infection was observed, the leaves were examined for disease development. Disease control values were recorded as percent control. Cucumber Anthracnose (CA) The fungal pathogen Colletotrichum lagenarium was cultured on potato dextrose agar (PDA) in the dark at 22 C for a period of 8 to 14 days. Spores of C. lagenarium were removed from the PDA plates by flooding the plate surface with distilled water, amended with 0.5% v/w of yeast extract. The upper surface of the fungal colony was scraped with a blunt instrument until most of the spores were released into the aqueous environment. The spore suspension was filtered though cheesecloth, and the spore count was adjusted by adding more water, containing the yeast extract, until 3.0 x 10 6 spores per ml of water was achieved. Tomato Early Blight (TEB) Cultures of Alternaria solani were grown on V-8 juice agar plates at room temperature under fluorescent lights (12 hr light, 12 hr dark) for 2 weeks. A suspension of the spores was obtained flooding the surface of the agar plate with a 0.5% solution of yeast extract in distilled water. The surface of the agar plate was scraped lightly with a blunt plastic instrument to release the spores into the liquid. The spore suspension was filtered through cheesecloth, and the spore concentration was adjusted to approximately 80,000 spores per ml. Tomato plants (cv. Patio hybrid) were approximately 18-days old at time of treatment with experimental compounds. Following treatment, the plants were placed in the greenhouse for 1 day. After this period, the plants were inoculated with freshly prepared spore suspension using a DeVilbiss atomizer. The spore suspension was applied to the upper surface of the leaves. After inoculation, the plants were placed in a Dew Chamber at 20°C for 24 hr to allow for infection. The plants were then transferred to a growth chamber at 22°C and 80% humidity for three days. Disease control values were recorded a percent control. The chemically-treated cucumber plants were 15-days old, cultivar Bush Champion. The upper leaf surface of the plants were sprayed with the spore suspension until runoff, using a hand-held pump spray bottle. The plants were placed in a fluorescent-lighted mist chamber (12 hr light, 12 hr dark) for 48 hours. After that infection period, the plants were placed in a growth chamber for 3 days at 25 C and 90% humidity. The treated plants were then evaluated for disease control. Disease control values were recorded as percent control. Wheat Helminthosporium (HEL) The fungal pathogen, Helminthosporium sativum (also known as Bipolaris sorokiniana), was cultured on V8 agar media at room temperature under fluorescent lights (12 hr on, 12 hr off) for a period of two to four weeks. Spores of H. sativum were removed from the V8 agar plates by flooding the plate surface with distilled water, amended with 0.5% v/w of yeast extract and 1 drop of Tween-80 per 100 ml. The upper surface of the fungal colonies were rubbed lightly with a plastic instrument until most of the spores were released into the aqueous environment. The spore suspension was filtered though cheesecloth, and the spore count was adjusted by adding additional water containing the yeast extract and Tween-80, until a spore count of 60,000 to 80,000 spores per ml was achieved. Chemically-treated wheat plants were sprayed with the spore suspension until runoff, using a hand-held pump spray bottle. The plants were placed in a fluorescent-lighted mist chamber for 24 hours. After that infection period, the plants were placed in a growth chamber for 1-2 days at 24 °C with 14 hour photoperiod and 20 °C at night. The treated plants were then evaluated for disease control. Disease control values were recorded as percent control. When tested against wheat leaf rust at 150 grams per hectare compounds 2.11, 2.166, 3.11, 3.14A, 3.166, 3.178, 9.16 and 9.22A exhibited 100% control and when tested at 38 grams per hectare compounds 2.12, 2.14A, 2.18A, 2.34, 2.70, 2.217, 3.12A, 3.17, 3.18A, 3.20, 3.34A, 3.40A, 3.70A and 9.200 exhibited 95% or better control. When tested against wheat leaf blotch at 150 grams per hectare compounds 3.11, 3.14A, 9.16 and 9.22A exhibited 90% or better control and when tested at 38 grams per hectare compounds 2.11, 2.12, 2.17, 2.18A, 2.166, 2.217, 3.12A, 3.17, 3.18A, 3.20, 3.34A, 3.70A, and 3.217A exhibited 90% or better control. When tested against wheat powdery mildew at 150 grams per hectare compounds 2.11, 2.166, 9.16, and 9.22A exhibited 90% or better control and when tested at 38 grams per hectare compounds 2.18A, 2.20, 2.70, 2.217, 3.20, 3.40A, and 3.217A exhibited 90% or better control. When tested against cucumber powdery mildew at a dose of 150 grams per hectare compounds 3.11, 3.14A, 8.16, 9.16 and 9.22A exhibited 100% control and when tested at 38 grams per hectare compounds 2.18A, 2.34, 2.217, 3.12, 3.17, 3.18A, 3.20, 3.34A, 3.40A and 3.217A exhibited 99% or better control. When tested against tomato late blight at 150 grams per hectare compounds 3.11, 3.14A, 8.16, 9.16 and 9.22A exhibited 95% or better control and when tested at 38 grams per hectare compounds 2.14A, 2.17, 2.18A, 2.20, 3.12A, 3.17, 3.18A, 3.20, 3.40A, 3.70A and 3.217A exhibited 95% or better control. When tested against grape downy mildew at 150 grams per hectare compounds 3.11, 9.16, and 9.22A exhibited 100% control. When tested against rice blast at 150 grams per hectare compounds 3.11, 3.14A, 8.16, 9.16, and 9.22A exhibited 95% or better control and when tested at 38 grams per hectare compounds 2.12, 2.14A, 2.18A, 2.20, 2.20B, 3.12A, 3.17, 3.18A, 3.20, 3.40A and 3.217A exhibited 90% or better control. When tested against cucumber downy mildew at 150 grams per hectare compounds 3.11, 3.14A and 9.16 exhibited 95% or better control and when tested at 38 grams per hectare compounds 2.14A, 2.17, 2.20, 3.17 and 3.20 exhibited 90% or better control and when tested at 9 grams per hectare compound 9.22A exhibited 100% control. When tested against cucumber anthracnose at 150 grams per hectare compounds compounds 3.11, 3.14A, 9.16 and 9.22A exhibited 100% control and when tested at 38 grams per hectare compounds 2.12, 2.14A, 2.17, 2.18A, 2.20, 2.34, 2.70, 2.166, 2.217, 3.12A, 3.17, 3.18A, 3.20, 3.34A, 3.40A, 3.70A, 3.166, 3.178, 3.217A, 8.16, 8.200 and 9.200 exhibited 95% or better control. When tested against tomato early blight at 38 grams per hectare compounds compounds 2.14A, 2.17, 2.20, 3.11, 3.14A, 3.17, 3.20, 3.166, 8.16, 9.16 and 9.200. exhibited 95% or better control. The surprising activity of the compounds of this invention is demonstrated through comparison of these compounds with similarly substituted compounds in tests as described above. The following table provides data for Example compound 9.16 (wherein 7 is 2,6-dichlorophenyl and Re is hydrogen) in a side- by-side compared to a similar compound wherein R7 is 4-fluorophenyl and Re is hydrogen (comparison example 1 - CE-1) and a compound wherein R 7 is 4- chlorophenyl and Re is hydrogen (CE-2): The following table provides data for Example compound 9.16 (wherein R 7 is 2,6-dichlorophenyl and Re is hydrogen) in a different side-by-side test compared to CE-1 and a similar compound wherein R 7 is phenyl and Re is hydrogen (CE-3): The following table provides data for Example compound 9.16 (wherein R 7 is 2,6-dichlorophenyl and Re is hydrogen and) in another side-by-side test compared to CE-2 (R 7 is 4-chlorophenyl and Re is hydrogen): The following table provides data for Example compound 3.11 (wherein Rε is methyl and R 7 is phenyl) in a side-by-side test compared to CE-3 (Re is hydrogen and R 7 is phenyl): The following table provides data for Example compound 3.20 (wherein Re is methyl and R 7 is 4-fluorophenyl) in a side-by-side test compared to CE-1 (wherein Re is hydrogen and R 7 is 4-fluorophenyl): The compounds of this invention are useful as agricultural fungicides and, as such, can be applied to various loci such as the seed, the soil or the foliage of plants to be protected. The compounds of this invention can be applied as fungicidal sprays by methods commonly employed, such as conventional high-volume hydraulic sprays, low -volume sprays, air-blast spray, aerial sprays and dusts. The dilution and rate of application will depend upon the type of equipment employed, the method of application, plants to be treated and diseases to be controlled. Generally, the compounds of this invention will be applied in amount of from about 0.005 kilogram to about 50 kilograms per hectare and preferably from about 0.025 to about 25 kilograms per hectare of the active ingredient. As a seed protectant, the amount of toxicant coated on the seed is usually at a dosage rate of from about 0.05 to about 20, preferably from about 0.05 to about 4, and more preferably from about 0.1 to about 1 grams per hundred kilograms of seed. As a soil fungicide the chemical can be incorporated in the soil or applied to the surface usually at a rate of from about 0.02 to about 20, preferably from about 0.05 to about 10, and more preferably from about 0.1 to about 5 kilograms per hectare. As a foliar fungicide, the toxicant is usually applied to growing plants at a rate of from about 0.01 to about 10, preferably from about 0.02 to 5, and more preferably from about 0.25 to about 1 kilograms per hectare. Inasmuch as the compounds of this invention display fungicidal activity, these compounds can be combined with other known fungicides to provide broad spectrum activity. Suitable fungicides include, but are not limited to, those compounds listed in U.S. Patent Number 5,252,594 (see in particular columns 14 and 15). Other known fungicides which an be combined with the compounds of this invention are dimethomorph, cymoxanil, thifluzamide, furalaxyl, ofurace, benalaxyl, oxadixyl, propamocarb, cyprofuram, fenpiclonil, fludioxonil, pyrimethanil, cyprodinil, triticonazole, fluquinconazole, metconazole, spiroxamine, carpropamid, azoxystrobin, kresoxim-methyl, metominostrobin and trifloxystrobin. The compounds of this invention can be advantageously employed in various ways. Since these compounds possess broad spectrum fungicidal activity, they can be employed in the storage of cereal grain. These compounds can also be employed as fungicides in cereals including wheat, barley and rye, in rice, peanuts, beans and grapes, on turf, in fruit, nut and vegetable orchards, and for golf course applications. Examples of diseases against which the compounds of the invention are useful include helminthosporium of corn and barley, wheat and barley powdery mildew, wheat leaf and stem rusts, barley stripe and leaf rust, tomato early blight, tomato late blight, peanut early leaf spot, grape powdery mildew, grape black rot, apple scab, apple powdery mildew, cucumber powdery mildew, brown rot of fruits, botrytis, bean powdery mildew, cucumber anthracnose, wheat septoria nodorum, rice sheath blight and rice blast Compositions and formulations according to the present invention may also include known pesticidal compounds. This expands the spectrum of activity of the preparation and may give rise to synergism. Suitable insecticides known in the art include those listed in U.S. Patent 5,075,471, see in particular columns 14 and 15. The compounds of the present invention can be used in the form of compositions or formulations. Examples of the preparation of compositions and formulations can be found in the American Chemical Society publication "Pesticidal Formulation Research," (1969), Advances in Chemistry Series No. 86, written by Wade Van Valkenburg; and the Marcel Dekker, Inc. publication "Pesticide Formulations", (1973) edited by Wade Van Valkenburg. In these compositions and formulations, the active substance is mixed with conventional inert agronomically acceptable (i.e., plant compatible and/or pesticidally inert) pesticide diluents or extenders such as solid carrier material or liquid carrier material, of the type usable in conventional pesticide compositions or formulations. By "agronomically acceptable carrier" is meant any substance which can be used to dissolve, disperse of diffuse the active ingredient in the composition without impairing the active ingredient's effectiveness and which by itself has no significant detrimental effect on the soil, equipment, desirable plants, or agronomic environment. If desired, adjuvants such as surfactants, stabilizers, antifoam agents and anti-drift agents may also be combined. Examples of compositions and formulations according to the invention are aqueous solutions and dispersions, oily solutions and oil dispersions, pastes, dusting powders, wettable powders, emulsifiable concentrates, flowables, granules, baits, invert emulsions, aerosol compositions and fumigating candles. Wettable powders, pastes, flowables and emulsifiable concentrates are concentrated preparations which are diluted with water before or during use. In such formulations, the compounds are extended with a liquid or solid carrier and, when desired, suitable surfactants are incorporated. Baits are preparations generally comprising a food or other substance attractive to insects, that includes at least one compound of the instant invention. It is usually desirable, particularly in the case of foliar spray formulations, to include adjuvants, such as wetting agents, spreading agents, dispersing agents, stickers, adhesive and the like in accordance with agricultural practices. A listing of such adjuvants commonly used in the art, and a discussion of adjuvants, can be found in many references, such as in the John W. McCutcheon, Inc. publication "Detergents and Emulsifiers, Annual." The active compounds of the present invention may be employed alone or in the form of mixtures with one another and/or with such solid and/or liquid dispersible carrier vehicles and/or with other known compatible active agents, especially plant protection agents, such as other insecticides, arthropodicides, nematicides, fungicides, bactericides, rodenticides, herbicides, fertilizers, growth- regulating agents, synergists. In the compositions of the invention, the active compound is present in an amount substantially between about 0.0001 (1:999,999) -99 (99:1) % by weight. For compositions suitable for storage or transportation, the amount of active ingredient is preferably between about 0.5 (1:199) -90 (9:1) % by weight, and more preferably between about 1 (1:99) -75 (3:1) % by weight of the mixture. Compositions suitable for direct application or field application generally contain the active compound in an amount substantially between about 0.0001 (1:999,999) -95 (19:1) %, preferably between about 0.0005 (1:199,999) -90 (9:1) % by weight, and more preferably between about 0.001 (1:99,999) -75 (3:1) % by weight of the mixture. The composition can also be stated as a ratio of the compound to the carrier. In the present invention the weight ratio of these materials (active compound/carrier) can vary from 99:1 (99%) to 1:4 (20%) and more preferably from 10:1 (91%) to 1:3 (25%). In general, the compounds of this invention can be dissolved in certain solvents such as acetone, methanol, ethanol, dimethylformamide, pyridine or dimethyl sulfoxide and such solutions can be diluted with water. The concentrations of the solution can vary from about 1% to about 90% with a preferred range being from about 5% to about 50%. For the preparation of emulsifiable concentrates, the compound can be dissolved in suitable organic solvents, or a mixture of solvents, together with an emulsifying agent to enhance dispersion of the compound in water. The concentration of the active ingredient in emulsifiable concentrates is usually from about 10% to about 90%, and in flowable emulsion concentrates, can be as high as about 75%. Wettable powders suitable for spraying, can be prepared by admixing the compound with a finely divided solid, such as clay, inorganic silicate and carbonate, and silica and incorporating wetting agents, sticking agents, and/or dispersing agents in such mixtures. The concentration of active ingredients in such formulations is usually in the range of from about 20% to about 99%, preferably from about 40% to about 75%. A typical wettable powder is made by blending 50 parts of a compound of Formula I, 45 parts of a synthetic precipitated hydrated silicon dioxide and 5 parts of sodium lignosulfonate. In another preparation a kaolin type (Barden) clay is used in place of the synthetic precipitated hydrated silicon dioxide in the above wettable powder, and in another such preparation 25% of the silicon dioxide is replaced with a synthetic sodium silicoaluminate. Dusts are prepared by mixing compounds of Formula I, or the enantiomorphs, salts and complexes thereof with finely divided inert solids which can be organic or inorganic in nature. Materials useful for this purpose include botanical flours, silicas, silicates, carbonates and clays. One convenient method of preparing a dust is to dilute a wettable powder with a finely divided carrier. Dust concentrates containing from about 20% to about 80% of the active ingredient are commonly made and are subsequently diluted to from about 1% to about 10% use concentration. In addition to the aforementioned ingredients the preparations according to the invention may also contain other substances commonly used in preparations of this kind. For example, a lubricant, such as calcium stearate or magnesium stearate, may be added to a wettable powder or to a mixture to be granulated. Furthermore there may, for example, be added "adhesives" such as polyvinylalcohol-cellulose derivatives or other colloidal materials, such as casein, to improve the adherence of the pesticide to the surface to be protected.

Claims: WE CLAIM: 1. A compound of the formula: wherein X is N or CH; Z is O, S, or NR 8 ; A is hydrogen, halo, cyano, (C 1 -C 12 )alkyl, or (^-C^alkoxy; R J L and R 8 are independently hydrogen or (C 1 -C 4 )alkyl; R 2 is hydrogen, (C 1 -C 4 )alkyl, halo(C 1 - C 4 )alkyl, (C 3 -C 6 )cycloalkyl, halo(C 3 - C 6 )cycloalkyl, (C 2 -C 4 )alkenyl, halo(C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, halo(C 2 -C 4 )alkynyl, or cyano; R 3 is hydrogen, (C r C 4 )alkyl, halo(C 1 - C 4 )alkyl, (C 3 -C 6 )cycloalkyl, halo(C 3 - C 6 )cyclo alkyl, (C 2 - C 4 )alkenyl, halo(C 2 - C 4 )alkenyl, (C 2 - C 4 )alkynyl, or halo(C 2 - C 4 )alkynyl; R 4 and R 5 are independently hydrogen, (C x - C 4 )alkyl, halo(C 1 - C 4 )alkyl, (C 3 -C 6 )cycloalkyl, halo(C 3 -C 6 )cycloalkyl, (C 2 - C 4 )alkenyl, halo(C 2 - C 4 )alkenyl, (C 2 -C 4 )alkynyl, halo(C 2 - C )alkynyl, halo, cyano, or (C C 4 ) alkoxycarb ony 1; and wherein A) R 7 is aryl or heterocyclic ring wherein the aryl or heterocyclic ring is substituted with from 2 to 5 substituents and wherein the positions on the aryl or heterocyclic ring adjacent to the bond to the cyclopropyl ring are both substituted and R 6 is hydrogen, (C r C 4 )alkyl, halo(C 1 - C 4 )alkyl, (C 3 -C 6 )cycloalkyl, halo(C 3 -C 6 )cycloalkyl, (C 2 - C 4 )alkenyl, halo(C 2 - C 4 )alkenyl, (C 2 - C 4 )alkynyl, halo(C 2 - C 4 )alkynyl, halo, cyano, or (CN C ) alkoxycarbonyl; or B) R 7 is an aryl or heterocyclic ring wherein the aryl or heterocyclic ring is unsubstituted or substituted from 1 to 4 substituents wherein at least one of the positions on the aryl or heterocyclic ring adjacent to the bond to the cyclopropyl ring is a hydrogen and R 6 is selected from the group consisting of (C r C 4 )alkyl, halo^- C 4 )alkyl, (C 3 -C 6 )cycloalkyl, halo(C 3 - C 6 )cycloalkyl, (C 2 - C 4 )alkenyl, halo(C 2 - C 4 )alkenyl, (C 2 - C 4 )alkynyl, halo(C 2 - C 4 )alkynyl, halo, cyano, or (C j -C^alkoxycarbonyl; and their salts, complexes, enantiomorphs, stereoisomers; and mixtures thereof. 2. The compound of claim 1, wherein X is CH, Z is O, R 2 is (C^C^alkyl, and R 3 is H. 3. The compound of claim 2, wherein R 7 is 2,6-dichlorophenyl, 2,6- difluorophenyl, 2,6-dibromophenyl, 2,6-bis(trifluoromethyl)phenyl, 2,3,6- trichlorophenyl, 2,3,6-trifluorophenyl, 2,3,6-tribromophenyl, 2,3,6- tris(trifluoromethyl)phenyl, 2,4,6-trichlorophenyl, 2,4,6-trifluorophenyl, 2,4,6- tribromophenyl, or 2,4,6-tris(trifluoromethyl)phenyl. 4. The compound of claim 2, wherein R 7 is 2,6-difluorophenyl or 2,6- dichlorophenyl. 5. The compound of claim 1, wherein X is N, Z is O or NH, R 2 is (C j^ -C^alkyl and R 3 is H. 6. The compound of claim 5, wherein R 7 is 2,6-dichlorophenyl, 2,6- difluorophenyl, 2,6-dibromophenyl, 2,6-bis(trifluoromethyl)phenyl, 2,3,6- trichlorophenyl, 2,3,6-trifluorophenyl, 2,3,6-tribromophenyl, 2,3,6- tris(trifluoromethyl)phenyl, 2,4,6-trichlorophenyl, 2,4,6-trifluorophenyl, 2,4,6- tribromophenyl, or 2,4,6-tris(trifluoromethyl)phenyl. 7. The compound of claim 5, wherein R 7 is 2,6-difluorophenyl or 2,6- dichlorophenyl. 8. The compound of claim 1, wherein the compound is N-methyl-2-[2-((trans-l- (2-(2',6'-dichlorophenyl)cyclopropyl)ethylidene)aminooxymethyl)phenyl]-2- methoxy imino acetamide . 9. The compound of claim 2, wherein R 6 is (C 1 -C 4 )alkyl and R 7 is phenyl, 2- chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-bromophenyl, 2-(trifluoromethyl)phenyl, 2,4-dichlorophenyl, 2,4-difluorophenyl, 2,4- dibromophenyl, 2,4-bis(trifluoromethyl)phenyl, 2-chloro-4-fluorophenyl, or 2- fluoro-4-chlorophenyl. 10. The compound of claim 5, wherein R 6 is (C 1 -C 4 )alkyl and R 7 is phenyl, 2- chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-bromophenyl, 2-(trifluoromethyl)phenyl, 2,4-dichlorophenyl, 2,4-diifluorophenyl, 2,4- dibromophenyl, 2,4-bis(trifluoromethyl)phenyl, 2-chloro-4-fluorophenyl, or 2- fluoro-4-chlorophenyl. 11. The compound of claim 1 where the compound is N-methyl 2-[2-((trans-l-(2- (4'-fluorophenyl)-2-methylcyclopropyl)ethylidene)aminooxymethyl)phenyl]-2- methoxyiminoacetamide, N-methyl 2-[2-((trans-l-(2-(2',4'-difluorophenyl)-2- methylcyclopropyl)ethylidene)aminooxymethyl)phenyi]-2- methoxyiminoacetamide, methyl 2-[2-((trans-l-(2-(2',4'-difluorophenyl)-2- methylcyclopropyl)ethylidene)aminooxymethyl)phenyi]-2- methoxy imino acetate . 12. A method of preparation of the compounds of claim 4 wherein X is N, Z is O, and R 6 is (C j^ -C^alkyl comprising the step of reacting methyl (E)-2- (aminooxymethyl)phenyl glyoxylate O-methyloxime with a 1-aryl or 1- heteroaryl-l-(C 1 -C 4 )alkyl-2-((C=O)(C 1 -C 4 )alkyl)cyclopropane. 13. A fungicidal composition comprising an agronomically acceptable carrier and the compound of claim 1, wherein the ratio of the carrier to the compound is between 99:1 and 1:4. 14. A method for controlling phytopathogenic fungi which comprises applying the compound of claim 1 to the locus where control is desired, at a rate of from 0.005 to 50 kilograms per hectare.

Inventors: NGUYEN DUYAN VUONG, ROSS RONALD JR, SHABER STEVEN HOWARD, SMITH FRISBY DAVID, SZAPACS EDWARD MICHAEL, NGUYEN, DUYAN, VUONG, ROSS, RONALD, JR., SHABER, STEVEN, HOWARD, SMITH, FRISBY, DAVID, SZAPACS, EDWARD, MICHAEL
Applicants: NGUYEN DUYAN VUONG, ROHM & HAAS, ROSS RONALD JR, SHABER STEVEN HOWARD, SMITH FRISBY DAVID, SZAPACS EDWARD MICHAEL, NGUYEN, DUYAN, VUONG, ROHM AND HAAS COMPANY, ROSS, RONALD, JR., SHABER, STEVEN, HOWARD, SMITH, FRISBY, DAVID, SZAPACS, EDWARD, MICHAEL
Application year: 2001
Main classification: C07C251
IPC codes: A01N37, A01N43, A01N53, A01P3, C07C251